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8Chapter 1
Introduction
Parts Published in “Away with the needle. Noninvasive administration routes for 
insulin: improved quality of life for diabetics”
Pharmazie in unserer Zeit
Deutsche Pharmazeutische Gesellschaft, DPhG
Volume 30(2) 136-141, 2001
91.1. Rationale of Systemic Delivery of Peptides and Proteins Across
Absorptive Mucosae
Advances in biotechnology have accelerated the economical, large-scale production of 
therapeutically active peptides and proteins, making them readily available for therapeutic 
use. In most cases such compounds are indicated for chronic therapy, and they will need to be 
administered by an appropriate delivery system. Although the oral route is preferred for the 
administration of drugs, particulary those required in chronic therapies, this is not feasible for 
the systemic delivery of most peptide and protein drugs (1). Their rapid hydrolytic and 
enzymatic degradation in the hepatogastrointestinal “first-pass” elimination renders oral 
administration impractical. The general approach to deliver  peptides and proteins has been 
parenteral administration, which is invasive and inconvenient. As a result, transmucosal 
delivery of peptide- and protein-based pharmaceuticals has been actively investigated in 
recent years, and some products are already  available on the market. This route offers the 
advantage of being non-invasive, and it holds great potential for the application of rate-
modulated delivery systems.
Two major barriers a.) the physicochemical barrier, stemming from the physiology and 
histology of the various mucosae and b.) the enzymatic barrier, impede successful 
transmucosal delivery (2). The former effectively deters permeation of large macromolecules, 
while the latter works in tandem to break down peptides and proteins of any sizes. Thus, 
bioavailabilities of peptides and proteins are usually less than 1% on transmucosal 
administration if no other adjuvants are added. To counter these barriers and to increase 
bioavailability, several approaches have been used. Enzyme inhibitors and permeation 
enhancer represent two classes of adjuvants that have been used effectively, albeit not always 
safely. The present popular approach has been to use biodegradable polymers for nano-
/microparticles, which stabilize the peptide and allow for a controlled-release delivery system.
10
1.2.  Non-invasive insulin delivery across mucosal surfaces
1.2.1. The most important therapeutic protein: Insulin
Insulin is synthesized in humans and other mammals in beta cells (B-cells) of the islets of 
Langerhans in the pancreas. One to three million islets of Langerhans (pancreatic islets) form 
the endocrine part of the pancreas, which is primarily an exocrine gland. The endocrine part 
accounts for only 2% of the total mass of the pancreas. Within the islets of Langerhans, beta 
cells constitute 60-80% of all the cells. Insulin comprises 51 amino acids and is one of the 
smallest proteins known; shorter 'proteins' are usually referred to as (poly)peptides. Beef 
insulin differs from human insulin in two amino acids, and pork insulin in one. Fish insulins 
are resembling human insulin and show hormonal activity in man.
Insulin is structured as 2 polypeptide chains linked with 2 sulfur bridges and has a molecular 
weight of about 5.7 kDa (see figure 1).
Chain A consists of 21, and chain B of 30 amino acids. Insulin is produced as a prohormone -
proinsulin that is later transformed by proteolytic action into the active hormone.
Figure 1.
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The actions of insulin on the human metabolism level include: 
• cellular uptake of certain substances, most prominently glucose 
• increase of DNA replication and protein synthesis
• modification of the activity of numerous enzymes (allosteric effect) 
• increased glycogen synthesis → causes storage of glucose in liver (and muscle) cells in 
the form of glycogen 
• increased fatty acid synthesis → causes fat cells to take up glucose which is converted 
to fatty acids 
• increased esterification of fatty acids → causes adipose tissue to make fats 
(triglycerides) from fatty acid esters 
• decreased proteinolysis → causes reduction of protein degradation 
• decreased lipolysis → causes reduction in conversion of fat cell lipid stores into blood 
fatty acids 
• decreased gluconeogenesis → decreases production of glucose from various substrates 
in liver
An insufficient insulin production, a resistance to insulin or a combination of both, causes a 
serious disease: Diabetes mellitus.
1.2.2. Major types of Diabetes mellitus
Type 1 Diabetes
Type 1 diabetes can develop at any age; however, it usually develops in children and young 
adults, which is why it was formerly designated juvenile diabetes. The classifcation was 
previously based on the need for insulin (insulin-dependent diabetes mellitus, IDDM),
because insulin injections must be taken daily. Now, the type of diabetes is determined by the 
etiological process rather than the treatment modality. Type 1 diabetes is thus characterized 
by islet cell destruction and type 2 diabetes by a combination of defects in insulin secretion 
and action. About 5% to 10% of all people with diabetes have type 1 diabetes. Type 2 
diabetes is the most common type of diabetes, and gestational and secondary diabetes are
other forms of the disease. Type 1 diabetes develops because of an autoimmune response in 
which the body destroy its own pancreatic beta cells. What causes the autoimmune response is 
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unknown. However, it is discussed that the disease may not develop without the presence of 
environmental factors, such as exposure to certain viral infections (Coxsackie B).  People who 
have first grade relatives with type 1 diabetes are more likely to develop the disease; however, 
most people with type 1 do not have a family history of the disease. Other factors that 
increase a person's risk are being white and having islet cell antibodies in the blood. 
Type 2 Diabetes
Type 2 diabetes is a lifelong disease that develops when the pancreas cannot produce enough 
insulin or when the body's tissues become resistant to insulin. Blood sugar can rise to an 
unsafe level even before diabetes symptoms occur. Type 2 diabetes can develop at any age, 
although it usually develops in adults (adult-onset diabetes). It was also called non-insulin-
dependent diabetes mellitus (NIDDM), because it can often be treated without using insulin.
Between 90% and 95% of all diabetics have type 2 diabetes. Some people believe, incorrectly, 
that type 2 diabetes is a milder form of the disease than type 1 diabetes, but it can cause the 
same harmful effects as type 1. Type 2 diabetes is caused by insulin resistance, which occurs 
when the body's cells and tissues do not respond properly to insulin. Weight, level of physical 
activity, and family history affect how the body responds to insulin. People who are 
overweight, get little or no exercise, or have diabetes in their family have an increased risk of 
developing type 2 diabetes. The conventional treatment of typ 2 diabetes includes a balanced 
diet, oral anti-diabetics and if necessary insulin substitution.
1.2.3. Conventional insulin therapy
The subcutaneous route, requiring single or multiple daily injections, is the mainstay of 
conventional insulin therapy. There are numerous disadvantages to injectable insulin therapy: 
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Poor patient compliance due to pain or discomfort, inconsistent pharmacokinetics, adipolysis 
at the site of injection and social stigma. 
For no other protein, such an enormous research effort was spent in the last decades, on 
academic as well as industrial level, to develop non-invasive delivery systems. Not at least do 
to the increasing number of people worldwide affected by diabetes, e.g. 2002 in the US 13,0
million people with diagnosed diabetes (American Diabetes Association), a huge commercial 
potential for a non-invasive insulin delivery system can be assumed.
The therapeutic insulin era began in 1922 with the first clinical use of insulin by Banting and 
Best. In the ensuing 80 years, scientists uncovered the basic pathophysiology of diabetes, 
gradually elucidated insulin structure and focused their attention on developing better insulin 
formulations (e.g. NPH, lente). Despite these advances, mimicking physiological patterns of 
insulin secretion has proven to be virtually impossible and the goal of restoring and 
maintaining blood glucose and other metabolic parameters at near normal levels in diabetic 
patients are elusive (3). Vascular complications due to the long-term dysmetabolic milieu 
remain a major cause of morbidity and mortality among diabetic patients. The administration 
of insulin in the form of a bolus subcutaneous injection has been the basis of insulin therapy 
since its introduction. However, this feature is central to the problem of glycaemic control 
since the pharmacokinetics of conventional insulin preparations given by this route make it 
virtually impossible to replicate the physiological pattern of nutrient-related and basal insulin 
secretion. Improvements in glycaemic control are expected with the combined use of rapid-
acting (e.g. lispro, aspart, glusiline) and long-acting insulin analouges (e.g. glargine, detemir) 
given by the s.c. route (4,5). However, dependence on s.c. administration of insulin to 
improve glycaemic control has resulted in increasingly complex and intensive insulin regimes 
involving multiple daily injections, or continuous insulin infusion using a variety of pumps 
aided by increasingly sophisticated glucose monitoring devices. Attempts to develop 
alternative routes of administering insulin began soon after the introduction of insulin therapy 
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in the 1920s. Since then, almost every conceivable route has been studied, including rectal, 
ocular and vaginal delivery, but these with limited success. Some of the most promising 
routes, strategies and commercial developments, particular in phase III clinical trials, are
shortly reviewed in the following chapter.
1.2.4. Strategies of non-invasive insulin delivery
Peroral (enteric-gastrointestinal)
From all possible application routes, the oral administration of insulin provides by far the 
greatest challenge. Polypeptides are degraded in the acidic environment of the stomach and by 
digestive enzymes, especially in the small intestine. Numerous individual and combined 
strategies have been devised to enhance insulin absorption. These include the co-
administration of insulin with enzyme inhibitors and/or permeation enhancer, methods 
designed to improve insulin chemical stability and the use of muco-bioadhesives, liposomes, 
emulsions and polymer-based delivery systems. Coating with a pH dependent acrylic based 
polymer and its encapsulation in microspheres and nanoparticles (6-10). The most promising 
approach to date is hexyl-insulin-monoconjugate-2 (HIM2), a native recombinant insulin with 
a small polyethylene glycol 7-hexyl group attached to the position B29 amino acid lysine, 
currently in development (Nobex Cooperation and Glaxo Smith Kline). Preclinical and 
pharmacokinetic and safety data for HIM2 are running. Ongoing phase I and II clinical trials 
suggest that oral HIM2 has a bioavailability of ~ 5% and may result in an acceptable glucose-
lowering effect (11). While the concept is promising, its far away from approval and still 
faces significant hurdles.   
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Oral-buccal sublingual
The oral mucosa offers a number of attractive features for administration of polypeptide 
drugs. The oral cavity is easily accessible, has a large surface area (100-200 cm2) with little 
proteolytic activity and is highly vascularized. However, in practice the multilayered structure 
of the squamous epithelium of the buccal and sublingual mucosae combined with the 
continuous but highly variable flow of salvia in the mouth constitutes an effective barrier to 
absorption. The use of absorption enhancer (surfactants, bile salts, chelators, alcohol and fatty 
acids), alone or combined with bioadhesive delivery systems (gels, films, patches) has been 
extensively tested in animal studies. Furthermore the addition of enzyme inhibitors and/or 
molecular modifications to increase the lipophilicity of the insulin molecule (conjugation with 
various polymers, acylation, methylation) and the use of prodrugs (12,13). Further efforts 
have been made to develop mucoadhesive delivery systems (14) and liposomal formulations, 
including highly deformable lipid vesicles (transferosomes) (15). A liquid aerosol formulation 
comprising mixed micelles made from a combination of absorption enhancers has been 
developed by Generex Biotechnology Cooperation (Toronto, Canada), the Oralin (oral 
insulin spray) is delivered by the RapidMist metered-dose applicator (16). Local tolerability 
appears acceptable, but bioavailability remains low, necessitating repeated administrations.
Transdermal
Although the skin is easily accessible and has a large surface area (1-2 m2), it is relatively 
impermeable to large, hydrophilic polypeptides such as insulin. Attempts to optimize 
transdermal insulin delivery have involved breaking down or removing the lipid barrier, the 
stratum corneum by a variety of chemical, electrical or physical methods. Iontophoresis (17),
low- frequency ultrasound, phonophoresis (18) and/or the use of drug carrier agents (19) are 
the main methodologies being explored. Apart from the issue of safety of the various 
chemical and physical pretreatments used, the long-term biophysical impact of iontophoresis 
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remains uncertain. Altea Therapeutics (Atlanta, USA) has developed a transdermal patch (AT 
1391) that delievers basal insulin over a 12h period. It consists of a reusable disk-shaped 
device powered by a small battery, creating micropores by generating an electric pulse that 
vaporizes the epidermis. The second component is a patch that delivers insulin through the 
microscopic pores. Steady-state insulin levels occur within a couple of hours. The Altea 
system recently entered phase 1 clinical trials.
Pulmonary
The respiratory tract, with an estimated surface area of 140 m2, offers great potential for the 
delivery of polypeptide drugs. The alveolar surface, which accounts for > 95% of the 
absorptive area, is lined by a very thin (0.1-0.2 µm) vesiculated and richly perfused 
monolayer of epithelial cells, which allow for a rapid uptake and a fast onset of action after 
inhalation. Of the entirely new insulin delivery systems, the inhaled insulin is the most likely 
to make it to the marketplace. The breaktrough for pulmonary peptide delivery was in the 
1990´s when the importance of aerosol dynamics was recognized. Many factors are known to 
influence the site of deposition of inhaled particles, including size, aerodynamic diameter, 
surface morphology, charge, solubility and hygroscopicity (20). For optimal deep lung 
deposition efficacy, particles should have low velocity and a size between 1 and 3 µm in 
diameter. In this regard, the specific device has a major impact on the metabolic effect and on 
reproducibility of the applied insulin (21). Current pulmonary drug delivery systems include a 
variety of pressurized meterd dose inhalers (pMDI), dry powder inhalers (DPI), nebulizers 
and aqueous mist inhalers (AMI). Most of the recent clinical experience with inhaled insulin 
has been obtained using a dry powder formulation in the Nektar/Exubera device (Nektar 
Therapeutics Inc., San Carlos, CA, Aventis, Bridgewater, NJ, Pfizer, NY), or liquid aerosols 
formulations in the AERx Insulin Diabetes Management System (Aradigm Corp., Hayward, 
CA, NovoNordisk A/S, Copenhagen, Denmark) and in the Aerodose Inhaler (Aerogen Inc., 
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Sunnyvale, CA, USA). Other delivery technologies include the use of modified particles in 
the AIR Pulmonary Drug Delivery System (Advanced Inhalation research Alkermes, 
Cambridge, MA, Eli Lilley, Indianapolis) and in the form of Technosphere insulin 
(Mannkind Biopharmaceuticals, NY, USA) (8,22,23). Concerns still exists about side effects 
like cough caused by use of the inhalant devices, an increase of insulin antibodies and 
scarring in the lungs. Althouh several of these devices are well into phase III trials, 
application for FDA approval is not expected this year as studies continue to verify the safety 
of these products .
1.2.5. Focus: Nasal insulin delivery
Even if the emphasis of current efforts is concentrated on pulmonary insulin delivery, there is 
also the nasal application of insulin in form of nosespray/-drops still highly interesting. The 
nasal application of peptides is the only route of administration from the mentioned non-
parenteral delivery concepts, that has gained numerous regulatory approvals so far:
• Miacalcin: Calcitonin, Mw 3500 (Novartis) 
• Synarel: Nafarelin acetate (Mw 1322), Gonadotropin releasing hormone GnRH
(Pharmacia/Pfizer)
• DDAVP: Desmopressin, Mw 1068 (Ferring)
• Suprefact: Buserelin, Mw 1300 (Aventis)
• Syntocinon: Oxytocin, Mw 1007 (Novartis)
These drugs are characterized by a low molecular weight and a high potency. Thus, 
therapeutic plasma concentrations of these drugs can be achieved at relatively low doses. In 
contrast, a marketable insulin preparation would require much higher bioavailabilities. A 
nasal insulin delivery is therefore a much greater challenge.
The nasal cavity offers an epithelial surface of approximately 150 cm2 but the main barriers 
include the very active mucociliary clearance mechanism and the presence of proteolytic 
enzymes. As early as 1923, Woodyatt attempted to administer insulin intranasally and in 
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1932, Collins and Goldzieher achieved sufficient insulin absorption across the nasal mucosa 
to produce a hypoglycaemic effect in subjects with diabetes mellitus. Progress in intranasal 
application of insulin has been dependent on the use of safe absorption promoters, which are 
able to enhance the absorption of insulin in clinically relevant doses (24). Table 2 summarizes 
insulin nasal absorption promoting systems. An extensive range of enhancer has been used to 
increase the absorption of insulin across the nasal  mucosa. These include bile salts and their 
derivatives, surfactants, fatty acids and their derivatives and cyclodextrins (25-27). Other 
methods used to improve insulin absorption involve inhibiting nasal proteases and/or 
retarding the removal of insulin with bioadhesives (26-28). The bioavailability of intranasal 
insulin varies according to the type, volume and concentration of both the enhancer and the 
insulin. Furthermore can the size, density, shape and hygroscopicity of the particles, the nasal 
airflow characteristics and the presence of any nasal pathology be of significant influence. In 
humans, when compared with s.c. route, nasal insulin absorption is much quicker, but the 
bioavailability is lower, at less than 20% (29), and the variability is higher (30). Clinical 
studies in patients with type 1 and type 2 diabetes have revealed a rapid but relatively short-
lived increase in plasma insulin following nasal administration with multiple doses required to 
control postprandial hyperglycaemia (31,32). However, metabolic control was frequently 
inferior to s.c. insulin and many patients suffered local nasal irritation (32,33). More recently, 
a lyophilized nasal insulin preparation containing sodium glycocholate given preprandially 
achieved glycaemic control equivalent to a regimen of twice daily NPH insulin in patients 
with type 2 diabetes over a 4-month period (34). A gel formulation developed subsequently
was found to have equivalent efficacy to s.c. insulin and improved nasal tolerance in type 1 
diabetes patients treated over a 6-month period (35). To date, the relatively limited clinical 
experience with intranasal insulin demonstrates a need for high and repeated doses to achieve
glycaemic control.
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Type of compound Enhancer/promoter Example Fab/Frel (%)1 Reference Possible mechanism of action of 
each class
Absorption enhancers
Bile salts
(and derivatives)
Sodium deoxycholate/ 
-glycocholate/
-taurodihydrofusidate
1% SDC spray
1% SGC spray
4% SGC spray
1% STDHF spray
1% STDHF spray
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12-12.5
67.5
11.4
7.1-9.2
Pontiroli A.E., Br. Med. J. 284 
(1982) 303-306
Moses A.C., Diabetes 32 (1983)
1040-47
Pozza G., Clin. Pharm.17 (1989) 
209-307
Nolte M.S., Horm. Metab. Res.
22 (1990) 170-174
Disrupt membranes, open tight 
junctions,
enzyme inhibition, mucolytic 
activity
Surfactants Sodium lauryl sulphate, saponin, 
polyoxyethylene-9-lauryl ether
0.8% Laureth-9 spray 21.6 Pontiroli A.E., Diabet. Metabol. 
13 (1987) 441-443
Disrupt membranes
Chelating agents Ethylenediaminetetraacetic acid, 
salicylates
-
Aungst B. J., Pharm Res. 5 
(1986) 305-308
Open tight junctions
Fatty acids
(and derivatives)
Sodium caprylate, sodium 
laurate, phospholipids (e.g. 
didecanoylphosphatidylcholine, 
lysophospatidylcholine)
2% DDPC spray
2% DDPC spray
6.4-11.2 / 20
8.8-13.2 / 9.9-
14.8
Drejer K., Diabet. Med. 9 (1992) 
335-340
Jacobs M.A., Diabetes 42 (1993)
1649-55
Disrupt membranes
Enzyme inhibitors Bestatin, amastatin, aprotinin - Morimoto K., Int. J. Pharm. 113 
(1995) 1-8
Enzyme inhibition
Miscellaneous Cyclodextrins, N-acetyl cystein, DM-CD powder (0.25 
mg/kg)
3.4-5.1 Merkus F.W., J. Control. Rel. 41 
(1996) 69-75
Disrupt membranes, open tight 
junctions
Bioadhesive materials
Powders Carbopol, starch microspheres, 
chitosan, albumin, starch
Starch microspheres 
Starch microspheres
Chitosan powder
Maize starch/ Carbopol 
974P powder
30
4.5
17.0
9.9-14.4
Bjork E., Int. J. Pharm. 47 
(1988) 233-238
Illum L., Int. J. Pharm. 57 
(1989) 49-54
Dyer A.M., Pharm. Res. 19 
(2002) 998-1008 
Callens C., J. Control. Rel.  66 
(2000) 215-220
Liquids, Gels Chitosan, carbopol, carboxy-
methylcellulose, hydroxypropyl-
cellulose
Carbopol gel 20.6 Najafabadi A.R., Drug Deliv. 11 
(5) 295-300 (2004).
Illum L., Pharm. Res. 11 (1994) 
1186-9
Morimoto K., J. Pharm. 
Pharmacol. 37 (1985) 134-136
Reduce nasal clearance, open tight 
junctions,
Table 2. Nasal absorption promoting systems
1
 Fab: absolute bioavailability, Frel: relative bioavailability (to subcutaneous route)
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The occurrence of nasal irritation and the potential for damage to the nasal mucosa and nasal-
ciliary function (36) are a cause for concern, especially when viewed in the context of the 
need for long-term exposure. In order for intranasal insulin to become a clinical viable 
alternative to s.c. insulin, major obstacles still remain to be overcome.
1.3. A novel nasal insulin delivery system for insulin
1.3.1. Multifunctional polymers: Bioadhesive and biodegradable
Bioadhesive polymers - multifunctional macromolecules which are able to increase the 
permeability of epithelial tissues and to simultaneously inhibit proteolytic enymes. By virtue 
of mucoadhesive properties these polymers make close contact to mucosa, thereby exerting 
such effects at locally high concentrations in a limited area. Desirable features: (a) no 
irritation or cell sensitivity, (b) sufficiently adhesive, (c) easily removeable. In the case of 
bioadhesive particulate drug delivery systems, the term bioadhesion is typically used to 
describe the adhesion between polymeric nanoparticles, either synthetic or natural, and soft 
tissues (i.e., gastrointestinal mucosa). Although the target of many bioadhesive delivery 
systems may be a soft tissue cell layer (i.e., epithelial cells), the actual adhesive bond may 
form with either the cell layer, a mucous layer, or a combination of the two. The process 
involved in the formation of such bioadhesive bonds has been described in two major steps
(37): 1. Contact stage: An intimate contact is formed between the mucoadhesive and mucuous 
membrane. 2. Consolidation stage: Various physicochemical interactions occur to consolidate
and strengthen the adhesive joint, leading to prolonged adhesion.
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It has been stated that at least one of the following polymer characteristics are required to 
obtain adhesion: 
(a) sufficient quantities of hydrogen-bonding chemical groups (OH) and  (COOH)
(b) anionic/cationic surface charges
(c) high molecular weight
(d) high chain flexibility
(e) surface tensions that will induce spreading into the mucous layer
Each of these characteristics favors the formation of bonds that are either chemical or 
mechanical in origin. Types of chemical bonds include strong primary as well as weaker 
secondary forces such as ionic bonds, van der Waals interactions, and hydrogen bonds. 
Although individually these forces are very weak, strong adhesions can be produced through 
numerous interaction sites. Therefore polymers with numerous reactive, polar groups such as 
carboxy- or hydroxyl-groups tend to develop intense mucoadhesive bonds.
For the nanocomplexes we employ polyvinylalcohol as basis, a polymer which exhibits a 
large quantity of such groups. In addition, a further synthetic modification through grafting 
with hydrophobic lactide groups or the charge modification by introduction of anionic 
sulfobutyl- or cationic amine-groups, favor and strengthen the bioadhesive character.
Potential advantages of nanoparticulate systems based on mucoadhesive polymers in drug 
delivery:
• Prolong delivery of drugs in all non-parenteral routes of administrations
• Localization for purposes of local therapy
• Targeting to specific diseased tissues
• Localization for purposes of
- permeability modification
- protease and other enzyme inhibition
- modulations of immunologic expression
• Improve the viability of non-parenteral, non oral routes of drug administration
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1.3.2. Self-assembly with insulin to nanocomplexes (NC)
Colloidal carriers may take many forms: liposomes, niosomes, nanoparticles and 
microemulsions. The conventional preparation techniques to manufacture nanoparticulate 
systems are based on emulsification, evaporation, solvent displacement and salting out
procedures. Commonly however these methods have the disadvantage of involving heat, 
sonication, organic solvents or toxical chemical crosslinking agents (38). Each of these factors 
can alter the delicate structure of insulin, resulting in its loss of bioactivity. Therefore a 
spontaneous self-assembly between insulin and a polymer to defined complexes, under gentle 
conditions, would be a promising approach.
The different amino acids side chains of insulin posses a variety of chemical and physical 
properties, which result in a behaviour far more complex than those of small ligands. All the 
interactions important for bioadhesion (electrostatic, hydrophobic, hydrogen bonds, steric 
effects) can occur simultaneously among insulin and segments of the polymer, directing both 
protein folding and complexation. The two most important parameters governing 
polymer/protein assembling in water are hydrophobic and electrostatic interactions. The 
association of both partners results in soluble species, including complexes with insoluble 
proteins such as membrane proteins, complex coacervation, precipitation, or gelation. In the 
case of soluble species the complexation possibly stops at an optimum size that is usually 
thought to be a balanced structure in euilibrium. Roughly summarized, three types of soluble 
mixed compounds have been observed (39): small “hairy” proteins (i.e. surrounded by many 
synthetic polymer chains), long “necklaces” containing several proteins along one polymer 
chain, and aggregates of both partners that did not sediment. 
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1.3.3. A novel class: watersoluble DEAPA polymers
In our working group a novel class of biodegradable polymers was synthesized and 
characterized (40). The polymers based on poly(vinyl alcohol) were charged modified, grafted 
with D,L-lactide and -glycolide and utilized e.g. for tetanus parenteral vaccination (41). The 
second generation of these graft polymers were composed of amine modified components
(diethylamino-propylamine, dimethylamino-propylamine, diethylamino-ethylamin) and 
proved to be useful for DNA delivery (42,43). This work focus on the water soluble polymers
of this class, which are characterized by short lactide side chains. (see figure 2).
poly(L-Lactic acid) (PLLA) grafting
dietylamino propylamine (DEAPA) group
acetate group
hydroxyl group
Figure 2: Drawing of a watersoluble DEAPA polymer demonstrating
the comb-like structure with multiple interaction sites.                                                                                    
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1.4. Objectives of this work
In this work, the short-chain comb polyesters are investigated for their suitability as a mucosal 
drug delivery system for insulin, with respect to:
Complexation with insulin (Chapter 2)
feasibility of self-assembling with insulin to obtain a stable colloidal solution
incorporation of insulin to the highest possible amount
controlling particle size in the nanometer range
stability in medium
binding characteristics of the complex
structure function relationships
In-vivo-investigations (Chapter 3)
feasibility of nasal insulin delivery with NC in a healthy rat model
transferability to a diabetic rat model
pharmacodynamic and pharmacokinetic parameters
relative and absolute bioavailability
structure, concentration / effect relationships
acute histological effects on the site of absorption 
In-vitro-characteristics (Chapter 4)
protection against enzymatic degradation
transport in cell culture model
cytotoxicity and reversibility
surfactant character of polymers
comparison of nanocomplexes with a DEAPA- nanoparticle formulation
Developing safe and effective nasal delivery systems for insulin is an exciting and demanding 
challenge and there is no doubt that the commercial availability of a nasal insulin formulation 
would represent a major breakthrough in the treatment of diabetes mellitus and help to 
improve the lives of millions of diabetics.
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Chapter 2
Self-Assembling Nanocomplexes from Insulin and Water-Soluble 
Branched Polyesters, Poly[(vinyl-3-(diethylamino)-propylcarbamate-
co-(vinyl acetate)-co-(vinyl alcohol)]-graft-poly(L-lactic acid): A 
Novel Carrier for Transmucosal Delivery of peptides.
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2.1. Abstract
The design of carriers for protein delivery that provide protection against enzymatic 
degradation and facilitate protein transport across epithelial surfaces, thus avoiding parenteral 
administration, remains a challenge. Self-assembling nanoscale protein/polymer complexes
might present a promising approach. We synthesized water-soluble, amphiphilic polyesters,
poly[(vinyl-3-(diethylamino)-propylcarbamate-co-(vinyl acetate)-co-(vinyl alcohol)]-graft-
poly(L-lactic acid), containing a positively charged backbone, and studied the spontaneous
formation of nanocomplexes (NC) with insulin. NC were characterized using dynamic light 
scattering, zeta-potential measurements, and atomic force microscopy (AFM). Insulin loading 
was determined with HPLC, and the binding constants were obtained by isothermal titration 
calorimetry (ITC). The NC formation was followed using nephelometric and light scattering 
techniques. Water-soluble, positively charged, branched polyesters with amphiphilic 
properties were obtained in a three-step polymer-analogous reaction. The degree of amine 
substitution, DS, in the PVAL backbone was varied between 0.04 to 0.5, and grafting this 
backbone with L-lactide increased the molecular weight from 18 kDa to 81 kDa. The polymer 
composition was optimized to facilitate NC formation with insulin resulting in a DS of 0.09
and a poly(L-lactide) side chain substitution of 0.5 with an average chain length of two lactic 
acids. Depending on polymer composition, stable NC of 200-500 nm diameter were formed 
with insulin, and the binding constants ranged from 4.7 × 105 to 9.5 × 106 M-1. Positively 
charged surface charges ranging from +5 to +35mV and an insulin loading up to 98% of 33 
I.U./ml were obtained. The NC visualized by AFM revealed spheroidal particles with an 
entangled internal structure. It was demonstrated that this class of multifunctional polymers is
capable of self-assembly with a peptidic substrate. The resulting nanosized complexes offer 
the potential for mucosal insulin/protein delivery and merit further investigations under in 
vivo conditions.
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2.2. Introduction
Diabetes mellitus is the most common of the serious metabolic diseases and prevalence in 
western societies is estimated to be about 1 %. Long-term complications involving the eyes, 
kidneys, nerves and blood vessels present a heavy burden for the health care system in 
western societies. The intensified insulin therapy for diabetic patients requires up to four 
subcutaneous injections per day to maintain adequate control of serum glucose levels. 
Compliance with such demanding dosing regimes is difficult for the patient and make the 
development of an alternative form of insulin administration clearly appealing.
Numerous attempts to deliver insulin by application routes avoiding injections have been 
reported in the literature. Peroral, pulmonary and nasal insulin administrations fall into this 
category, but enzymatic lability and inefficient transport across mucosae provide formidable 
challenges and lead to low and variable bioavailabilities (1). The intranasal route is most 
attractive for chronic administration of peptides and proteins (2). However, nasal insulin 
absorption is low without co-administration of absorption enhancers which open the epithelial 
barrier and/or prolong the residence time in the nasal cavity. Promoters such as bile salts, 
chelating agents or the surfactant laureth-9 have shown undesirable toxic side effects after 
chronic administration (3).
Proteins delivery systems relying on complexation and assembly of proteins with amphiphilic 
polymers could present an alternative to the absorption enhancers described above. These 
polymers form nanoscale complexes with proteins through electrostatic and van der Waals 
interactions, protecting them against loss of biological activity and increasing their 
transmucosal uptake. Several polymers such as chitosan (4), poly(glutamine) (5), 
poly(ethylenimine-co-polyester) (6), AB block-copolymers, e.g. PEO-poly(L-lysine) (7) or 
PEO-PLGA (8), polyacrylates (9,10) or poly(L-lysine) derivates (11) have been proposed for 
insulin delivery. 
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Nanoscale delivery systems with strong bioadhesive properties seem to be a promising 
approach (12) because significant insulin uptake after nasal or oral administration without use 
of penetration enhancers was observed. Nanoparticles, (NP), of insulin and chitosan were 
obtained in the size range of ca. 350 nm by ionotropic gelation, leading to blood glucose 
reduction in rabbits after nasal administration (4). Oral administration of insulin containing 
NP (~ 700nm) from a fumaric and sebacic acid copolyanhydride resulted in a significant 
blood glucose reduction and strong adhesive NP/mucus interactions (13). For intranasal drug 
delivery polymers with positively charged groups like chitosan, poly-L-lysines or protamine 
has been demonstrated to increase bioadhesion and membran permeability (3) . 
Another important concern is the fabrication of NP. Nano-encapsulation techniques often rely 
on formation of emulsions with subsequent solvent evaporation. Usually a high energy input 
is necessary to obtain nano-emulsions and hence NP.  Under those conditions protein stability 
is often compromised through temperature-, pH-, and shear stress at interfacial surfaces with 
organic solvents (14). 
Therefore, a self assembling system composed of an “intelligent” polymer designed for 
spontaneous complexation of a target-protein under gentle aqueous conditions might provide 
advantages over classic nano-encapsulation strategies. Since the pioneering work of 
Morawetz and Hugues (15), it is recognized that globular proteins can form stable complexes 
with polyelectrolytes. The association of proteins with polyelectrolytes can result in soluble 
complexes, complex coacervation, precipitation or gelation of the resulting system (16,17). 
The two most important parameters governing polymer/protein association in water are the 
hydrophobicity and the electrostatic interactions of the partners. Additional phenomena, such 
as gelation and retardation of precipitation, are thought to result directly from the presence of 
hydrophobic association in polyelectrolyte complexes (PEC) (18). 
Optimal polymer properties for self-assembly with proteins are rarely found in naturally 
occurring macromolecules. We report here the design and characterization of new synthetic 
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polymers with amphiphilic properties suitable as self-assembling protein carrier system . By 
grafting L-lactide onto a hydrophilic, charge-modified poly(vinyl alcohol) backbone with 
covalently bound diethylamino-propylamine groups, amphiphilic biodegradable comb 
polyesters with lipophilic side chains were obtained. We hypothesized that insulin, dissolved 
at a pH above its point of isocharge (PI ~ pH 5.3), carries an overall negative charge (19) and 
will form PEC with the cationic polymers by electrostatic and hydrophobic interactions. This 
work is an extension of our experiments using negatively charged branched polyesters, 
namely SB-PVA-g-PLGA for transmucosal delivery of tetanus toxoid (20,21).
2.3. Materials and Methods
2.3.1. Materials
Diethylaminopropylamine (purum, >98%), poly(vinyl alcohol) (PVA) (15000 g/mol; degree 
of polymerization 300 (P=300); degree of hydrolysis 86-89%), carbonyl di-imidazole, (CDI), 
(purum, 97%), N-methyl pyrrolidone (NMP) (purum, absolute) and 1,3-Dimethyl-3,4,5,6-
tetrahydro-2(1H)-pyrimidinone (DMPU) (puriss., absolute, over molecular sieve) were 
purchased from Fluka GmbH Germany and used as received. L-lactide(S-grade) (Boehringer 
Ingelheim, Germany) was recrystallized twice from ethyl acetate. Tin(II) 2-ethylhexanoate 
(Aldrich, Germany) was used as received. Tetrahydrofuran (THF) (BASF, Germany) was 
dried over sodium and distilled under nitrogen before use. N,N-Dimethylacetamide (for 
HPLC, 99.8%)  was purchased from Fluka and Lithium bromide (extra pure) was ordered 
from Merck. Human recombinant insulin powder (26.2 I.U./mg) was a gift from Aventis 
Pharma AG (Germany). All other chemicals were of the highest analytical grade 
commercially available.
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2.3.2. Polymer synthesis
The synthesis was described in detail elsewhere (22). Poly[(vinyl-3-(diethylamino)-
propylcarbamate-co-(vinyl acetate)-co-(vinyl alcohol)]-graft-poly(L-Lactic acid) were 
synthesized in a three-step synthesis. Briefly, amino functions were introduced to the PVA 
backbone using CDI linker chemistry followed by grafting of L-Lactic acid chains using a 
ring-opening polymerization in bulk. The products were purified by ultrafiltration and 
lyophilized.
2.3.3. Nomenclature
The source-based IUPAC nomenclature for these polymers is Poly(vinyl 3-
(diethylamino)propylcarbamate-co-vinyl acetate-co-vinyl alcohol)-graft-poly(L-lactide). As 
abbreviation we used ‘DEAPA’ (diethylaminopropylamine) followed by the average number 
of amine carrying monomer units per ‘PVA’ (poly(vinyl alcohol)) chain with a 
polymerization degree of 300. The grafting of PLLA with the average chain length in 
parentheses follows (e.g. DEAPA(26)-PVA300-g-PLLA(2)). One third of the average of amine 
carrying monomers of the backbone is the same like the degree of amine substitution (DS) of 
the PVA: e.g. a DS of 0.087 is equivalent to DEAPA(26)-PVA300. For simplification, the 
following code was selected: P for the DEA(P)A substitution, afterwards the number of amine 
groups per PVA in parentheses, followed by number of the lactide amount from feeding and 
LL as index, indicating grafting with pure L-Lactide side chains (e.g. P(26)-2LL). 
2.3.4. Polymer Characterization
1H and 13C NMR spectroscopic data were collected using a JEOL Eclipse+ 500 and a Joel 
GX 400 D at a frequency of 500 or 400 MHz for 1H NMR and 126 respectively 101 MHz for 
13C NMR at 50 °C in d6-DMSO (euriso-top, <0.02% HDO+D2O). 40 to 50 mg samples were 
used for each measurement. 1H NMR was performed with 64 and 13C NMR with 4096 scans.
34
Gel permeation chromatography (GPC) was performed using a SDV linearM column (8 x 300 
mm, 5µm, with pre-column 8 x 50mm) from Polymer Standard Services (Mainz). The eluent 
was dimethylacetamide with an addition of 2.50g LiBr/L and a flow rate of 0.5 ml /min at 
60°C. The GPC consisted of a Merck-Hitachi AS-2000A autosampler, an L-6000 pump, a 
Merck T-6300 Column Thermostat and Differential Refractometer Optilab DSP, a Wyatt 
DAWN Eos multi-angle-light-scattering detector (The dn/dc was calculated with total mass 
recovery, Dawn EOS calibrated against PMMA 200k) and a Duratec DDG-75 degasser. The 
molecular weights of the samples were determined (third order fit) with the Wyatt Astra 
V4.73 Software.
2.3.5. Nanocomplex Preparation and Characterization
Preparation of Insulin Nanocomplexes: An insulin stock solution (2.50 mg/ml) was prepared 
in two steps. 1. The insulin powder was dissolved in 87% (V/V) 1.15x10-2 N-HCl in 10,0 ml-
Pyrex tubes. 2. 13% (V/V) of 0.1 N-Tris(hydroxymethyl)aminomethane solution was added 
resulting in a clear Tris-buffer with low ionic strength (I=0.01) and pH 7.40. Polymer stock 
solutions in concentrations (table 2)  from 0.64 mg/ml for P(150) up to 7.0 mg/ml for P(26)-
3LL were prepared in Tris-buffer. An equal volume of the stock solutions of insulin and 
polymer were mixed resulting in defined mass ratios (table 2) of insulin/polymer 1: 0,26-2,8 
(m/m) in the final NC-solution. The colloidal polymer-insulin complexes formed immediately 
after mixing by spontaneous self-assembly. 
Particle Size and ζ- potential characterization: Average size and the size distribution of the 
NCs was investigated using photon correlation spectroscopy (21) with a Zetasizer 4 equipped 
with an AZ110 cell (Malvern Instruments UK), a 4-mV laser source, a 64-channel correlator, 
and a multi-angle photomultiplier. Each buffer solution was filtered through 0.2 µm-
Acrodisc filters (Gelman Laboratory) and measurements were performed in serial mode. 
The photon correlation spectroscopy (V.1.26 Software) was used to calculate particle mean 
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diameter and width of the fitted Gaussian distribution. The ζ-potential of the NC suspension 
was determined by laser-Doppler-anemometry in distilled water (conductance 0.055 µs/cm) 
using the AZ 104 cell. The ζ-potential was derived from electrophoretic mobility of the NC.
Each measurement was performed in triplicate.
Insulin Loading of Nanocomplexes: After centrifugation of the complex dispersions in 2.0 ml 
Eppendorf-Cups for 30 min at 14.000 U/min, the supernatant was filtered through 0.1 µm 
Millex (Millipore) and the insulin content was determined by high performance liquid 
chromatography (HPLC). HPLC was based on a LiChrosphere®100 RP18 (5µm), 250-4-
column (Merck) with isocratic elution (65% H2O + 0.1% TFA / 35% Acetonitrile 90/ H2O 10 
+ 0.1%TFA (flow rate 1.0ml/min) and detection of insulin by a fluorescence 
spectrophotometer (Ex 276nm/Em 600nm). The HPLC system consisted of a T6300 column 
thermostat, a 6200A pump, a F1050 fluorescence spectrophotometer, an AS 2000A 
autosampler (Merck, Germany) and a vacuum degasser (Duratec). Data processing was 
performed with the Millenium32 software Version 3.05. (Waters).
2.3.6. Isothermal Titration Calorimetry
Microtitration calorimetry was performed using the MSC-ITC equipment from Microcal Inc. 
(Northampton, USA). The cell volume was 1351 µl containing insulin and the syringe volume 
250 µl with the respective polymer solution. All Tris buffer solutions were filtered with 0.2 
µm-Acrodisc and the pH values in the final solutions were controlled to be 7.40 to avoid pH 
compensation signals. The injection scheme was 14 x 15 µl every 190 sec at 400 rpm at 25 °C 
and data processing was performed with the software Microcal Origin 3.5. The measurements 
were carried out in triplicate.
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2.3.7. NC stoichiometry by colloid titration
Turbidimetric measurements were carried out according to the method of Kokufuta et al. 
(23,24). A constant volume of 0.30 ml insulin stock solution (2.50 mg/ml) was mixed with an 
appropriate volume of polymer solution and filled up with Tris buffer to a constant volume of 
3.30 ml to avoid dilution effects. Transmission data were recorded on a Shimadzu UV-160 
spectrophotometer at 630 nm using Suprasil cuvettes with 10 mm path length. Scattering 
data were obtained in the same way as PCS at an angle of 90°. The extrema were read directly 
from curves after plotting the data points with B-spline connection using Microcal Origin 6.0 
software. Determinations were carried out in triplicate.
2.3.8. Atomic force microscopy
The polymer/insulin NC were prepared as described above. After 20 minutes, the complexes 
were directly transferred onto a silicon chip by dipping into the NC solution. Atomic force 
microscopy was performed on a Digital Nanoscope IV Bioscope (Veeco Instruments, Santa 
Barbara, CA) as described elsewhere (25). The microscope was vibration-damped. 
Commercial pyramidal Si3N4 tips (NCH-W, Veeco Instruments, Santa Barbara, CA) on a 
cantilever with a length of 125 µm, a resonance frequency of about 220 kHz and a nominal 
force constant of 36N/m were used. All measurements were performed in tapping mode to 
avoid damage of the sample surface. The scan speed was proportional to the scan size and the 
scan frequency was between 0.5 and 1.5 Hz. Images were obtained by displaying the 
amplitude signal of the cantilever in the trace direction, the height signal in the retrace 
direction, and the phase signal in retrace direction, both signals being simultaneously 
recorded. The results were visualized either in height, amplitude or/and in phase modus. The 
phase mode permits assessment of material properties (viscoelastic properties). These are 
expressed as “brightness” of the AFM image.
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2.4. Results and Discussion
2.4.1. Synthesis and Structural Characterization of the Copolymers 
Nanoscience is a rapidly developing area of research with considerable potential for drug 
delivery because cellular interaction and transport of nanoscale objects may offer new 
opportunities not available to larger devices. Especially NP based on 
hydrophilic/biodegradable polymers can be designed to provide particle characteristics, 
protease inhibition and permeation enhancement for peptidic drugs. 
To explore the potential of the NP approach, novel materials are necessary which allow 
formation of NP under mild conditions, such as self-assembly leading to nanocomplexes. We 
have designed amphiphilic charge-containing biodegradable copolyesters composed of a 
hydrophilic PVA backbone grafted with short hydrophobic lactic acid groups to complex 
proteins and peptides. Cationic carriers such as DEAE-dextran, chitosan and poly(L-lysin) are 
suitable for complexation of a large number of negatively charged pharmacologically active 
agents, e.g. insulin, oligonucleotides, and DNA  (26-28). The use of CDI chemistry allows the 
modification of amine-substitution in a broad range. We coupled amino-groups to the PVA 
backbone and investigated the effect of different degrees of DEAPA substitution on complex 
formation with insulin. PVA is known as a non-toxic and biocompatible polymer which 
exhibits mucoadhesive properties and is therefore used in drug delivery (29). The degree of 
amino-substitution was varied from moderate 13 (DS=0.04), up to a highly substituted 
backbones with 150 (DS=0.5) of the ca. 300 hydroxyl-groups of PVA substituted (c.f. Table 
1). To introduce amphiphilicity in the PVA backbone, hydrophobic L-lactic acid side chains 
were grafted to the backbone in a second step to yield a brush-like and biodegradable 
copolyester structure. For a P(26) backbone (DS=0.09), the highest possible lactic acid 
substitution while remaining water soluble was 1:3 (w/w). By combining hydrophilic 
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backbones with hydrophobic domains, numerous benefits were reported in literature such as 
increased drug loading, self-association or complex stability (18,30,31).
The polyesters were characterized using 1H-NMR spectroscopy and gel permeation 
chromatography. A typical 1H-NMR spectrum (Figure 1) of these graft polymers show signals 
of both polymers, PVA and poly(L-lactide). The ratio between end group and central group 
integrals depends on the side chain length and could be used to calculate the average chain 
length and the molecular weight (MW) of the sample. The reproducibility of the synthesis is
demonstrated for two different batches of polymer P(26)-2LL (Table 1, footnote f) with similar 
degrees of substitution. It could be shown that the MW of the polyesters is increasing as 
expected. The polymer with the highest calculated side chain length, P(26)-3LL, shows the 
highest molecular weight and the polymer with the lowest lactic acid grafting, P(26)-1LL, 
yields the smallest molecular weight of all polyesters. The molecular weights calculated from 
NMR spectra of all tested polymers are in good agreement with the number average 
molecular weights, Mn, obtained by GPC/MALLS. The only exception was P(26)-2LL, which 
exhibited an apparent higher molecular weight measured by light scattering caused by a 
fraction of polymer aggregates. Otherwise, the elution time of P(26)-2LL measured by a 
refractive index detector is in the range of the other polyesters (Figure 2), indicating a MW of 
the same order of magnitude. 
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Table 1. Physicochemical Properties of the Polymers
a
 Average lactic acid units per chain calculated by 1H NMR data. bMolecular weight calculated from 1H NMR data. cMolecular weights measured by GPC-
MALLS (dawn Eos + optilab). dPercent of hydroxyl groups carrying amine or lactid calculated on P (PVAL) = 300 (P: degree of polymerization). eHeavy 
polymer aggregation. fYield calculated on used educt masses and resulting product mass.
Table 2. Characterization of NC
Polymer Mass ratio:insulin/polymera
PCS:
NC sizes/nm
AFM:
NC sizes/nmb
AFM:
diameter/height
- Potential,
mV
Drug 
loadingc
Charge 
ratio +/-d
Stoichiometry:
turb./ITCe
DEAPA(13) 1 : 0.45 450 ± 89 - - 3.0 ± 0.4 20.4 ± 0.6 1.15 -
DEAPA(26) 1 : 0.50 394 ± 61 274 ± 68 1.04 17.7 ± 2.7 78.9 ± 1.2 0.97 12.4 / 22.0
DEAPA(68) 1 : 0.23 195 ± 30 - - 24.6 ± 3.2 94.0 ± 2.9 0.75 25.6 / 83.2
DEAPA(150) 1 : 0.26 430 ± 98 434 ± 43 1.27 34.6 ± 4.7 97.1 ± 2.5 0.61 45.4 / 164
DEAPA(26)-(1) 1 : 1.60 370 ± 48 418 ± 51 1.15 15.0 ± 2.4 72.4 ± 2.6 0.56 7.1 / 16.0
DEAPA(26)-(2) 1 : 1.70 250 ± 39 285 ± 65 1.07 18.8 ± 3.3 76.4 ± 13.4 0.75 9.5 / 16.0
DEAPA(26)-(3) 1 : 2.80
 290 ± 120 340 ± 86 1.35 32.7 ± 2.5 98.7 ± 0.1 0.50 -
a
 Optimized mixing ratios, standard insulin concentration 1.25 mg/mL in NC solution. bMeasured from 25 x 25 µm scale AFM images. c Determined by HPLC 
after filtration of NC with 0,22 µm. dRatios at the turbidimetric/scattering extrema. eMolar insulin/polymer ratio: first value at extrema turbidimetry, second value 
at turning point ITC.
Polymer Length of
side chaina MW, g/mol
b Mn/MW (by LS)c
g/mol
Substitution
(amine)d/%
Substitution
(lactide)d/%
Yield
(w/w)f/%
DEAPA(13) - 16200 14640 / 16640 4.4 - 78
DEAPA(26) - 17800 15410 / 19590 8.1 - 74
DEAPA(68) - 23900 33590 / 67790 22.7 - 42
DEAPA(150) - 38700 - 50.0 - 22
DEAPA(26)-(1) 2.1 34500 42940 / 81680 8.1 32.1 84
DEAPA(26)-(2) 3.1 51700 221900 / 3855000e 8.1 48.7 67
DEAPA(26)-(2) 2.8 48300 - 8.5 46.8 -
DEAPA(26)-(3) 4.3 74600 71550 / 124500 8.1 60.9 70
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Figure 1. 1H-NMR spectra of DEAPA (26)-(3) and the correlation of structure and signal.
The lactide chains have four different signals. These are the multiplet of the methine central 
groups between 5.24 and 5.03 ppm, the multiplet of the methine end group between 4.25 and 
4.15 ppm, the multiplet of the methyl central groups between 1.51 and 1.40 and the multiplet 
of the methyl end groups between 1.32 and 1.27.
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Figure 2. GPC signals of the refractive index detector of the polymers DEAPA-(26), -(26)-
(1), -(2) and -(3). There is only a small difference between the three polyesters. The modified 
PVA shows a higher eluation volume.
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2.4.2. Formation of NC with insulin
Complex formation between proteins and polymers is influenced by a large number of 
parameters. Apart from mixing conditions (polymer concentration, rate of mixing, stirring), 
medium parameters (pH value, ionic strength, type of salt, polarity of solvent) and particularly 
the characteristics of the polyelectrolyte (molecular weight, polydispersity, branching, charge 
density) are known to play an important role. We investigate the complexation process in a 
systematic manner using turbidity as a simple and non-invasive measurement of NC 
formation (32). The formation of supramolecular structures leads to a corresponding increase 
in particle mass, which can be sensitively monitored by light scattering. In turbidimetric 
studies, the transmission of a light beam passing through a cuvette with a dispersion is given 
by T= I/I0 = exp (-τ·l) where I0 is the intensity of the light beam, I is the intensity after the 
cuvette of the length l, and τ is the turbidity. In non-absorbing systems (630nm), the 
transmittance is determined by the scattering of light. According to the Rayleigh theory, the 
scattered intensity is proportional to the square of the particles mass (33,34). Turbidimetry 
monitors structural changes caused by the onset of association respectively particle formation. 
The characteristics of a turbidimetric curve for different mixing ratios of a 3.2 × 10-5 mol 
insulin solution with increasing concentrations of polymer are shown in Figure 3. 
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Figure 3. Turbidimetry () and scattering () of DEAPA(26) and insulin.
The graph does not represent a classic colloid titration because every data point was generated 
from a separate experiment with a constant volume of 3.30 ml to eliminate dilution effects. 
All polymers exhibited the same turbidimetric profile characterized by a sharp decrease of 
transmission and a sharp increase of scattered light at increasing polymer concentrations 
resulting in distinct minima and maxima. The turbidimetric profile suggests that at initially
low polymer concentration, large and incoherent complexes are formed with an excess of 
insulin. These complexes condense to a more defined and compact structure at increasing 
polymer concentration, corresponding to mixing ratios at the extrema and the ascending part 
of the turbidimetric curve. Furthermore, addition of the same type of polymer to NC 
dispersion leads to a redistribution of the insulin to the new binding partner resulting in a 
decrease of scattering intensity and absorption. The NC size measurements as a function of 
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the mixing ratios confirm this assumption (Figure 4). A transition to small sized NC was 
achieved upon exceeding the described minima/maxima. 
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Figure 4.  Size measurements for DEAPA(68) () and DEAPA(26)-(3) (). Dashed lines 
represent turbidimetric/scattering extrema: Abrupt size decrease to defined NC after 
exceeding critical mixing ratios.
At a physiological pH human insulin carries two negative charges per molecule (19). The 
terminal tertiary amino groups of DEAPA are predominantly protonated at neutral pH, 
allowing calculation of charge ratios at the extreme values of the turbidity curves. The 
calculations are based on the total concentrations. In Figure 5, a linear relationship between 
the number of DEAPA groups in the backbone and the molecular ratio of insulin/polymer is 
shown.
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Figure 5. Turbidimetric and scattering extrema: correlation of molecular ratio and 
substitution degree of DEAPA (,∆) respective amount grafted lactide (,). 
With higher degrees of amino substitution, increasing from 13 to 150, higher molar ratios 
between DEAPA and insulin with 1:7 up to 1:45 are observed. These data suggest that at the 
extreme values approximately 1:1 charge ratios are observed (Table 2) and highlight the 
importance of electrostatic interactions. On the other hand, with increasing amounts of lactic 
acid grafting is no change in the molar ratio of insulin/polymer is observed. This suggests that 
the stoichiometry of the complexes is primarily determined by coulombic interactions and that 
hydrophobic forces play a minor role. 
Under our experimental conditions, the NC demonstrated no tendencies of precipitation or 
macroscopic flocculation. The only exception is P(26)-3LL-NC which tended to precipitate 
after ~1-2 hours, possibly due to the high lactic acid grafting. It is very important to mention 
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that turbidimetry does not provide information on the affinity between insulin and the 
different polymers. Therefore, isothermal microtitration calorimetry was performed.
2.4.3. Nanocomplex Characterization
Ideal nanocomplex containing insulin should meet the following requirements: (i) particle 
sizes < 500nm to facilitate epithelial uptake (35); (ii) high positive ζ−potential to increase 
interaction with negatively charged cell surfaces (36); and (iii) high insulin loading. These 
parameters were determined at different points of the turbidimetric profile (figure 4). It was 
found that the optimal range is located at the ascending part of the profile. This observation 
was made with all polymers and thus permitted a calculation and even a prediction of the 
optimal ratios of both binding partners (Table 2). 
Using a simple mixing procedure and short incubation times, it was possible to obtain NC 
with an average diameter of ~200 to 500 nm. Within a homologous series of backbone 
composition, an increasing amount of lactic acid grafting (0 < 1LL < 2LL) led to more compact 
and smaller NC, pointing to the influence of hydrophobic interactions for the complex 
structure. The degrees of amino-substitution allowed variation of the positive surface charge 
of the NC. The observed ζ-potentials ranged from +3 mV at a low (‘13’) to + 35 mV with a 
higher degree of substitution (‘150’). Furthermore, when the number of amino groups was 
kept constant at 26 and the lactic acid ratio was increased from 1LL to 3LL the ζ-potential 
increased from +15 mV to +33 mV. This could be explained by increased internal 
hydrophobic interactions leading to a displacement of positive charges from the inner parts of 
the complex to the outer layer. 
The high loading of insulin (Table 2) in NC was obtained either with high degrees of amine-
substitution or by a combination of medium charge density (‘26’) and a higher lactic acid 
grafting (2LL, 3LL). At the standard concentration of 1.25 mg/ml insulin (26.2 I.U./mg) ca. 
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98% were bound in NC. A degree of amino-substitution of 0.04 was insufficient for sufficient 
insulin complexation. 
The hydrophobic B-chain, C-terminal end plays an important role in the complexation 
behavior of insulin (e.g. self-association or fibrillation). The increased complexation capacity 
of the higher grafted polyesters possibly results from more pronounced hydrophobic 
interactions with these nonpolar residues of insulin. In the literature, the formation of 
complexes was even observed with partners of the same charge, namely serum albumin and 
hydrophobically modified anionic polyacrylic acid (37), pointing to the importance of 
hydrophobic interactions. 
2.4.4. Microcalorimetry
Interactions between proteins and polymers and their assembly to NC, are the result of 
cooperative interactions of many weak inter- and intra-molecular forces. Isothermal titration 
calorimetry (ITC) provides a tool to determine equilibrium constants and enthalpies under 
identical experimental conditions. From these data, entropy values and standard free energies 
can be derived, giving insight into the complexation reactions. The binding constant, Kbin, 
allows an assessment of the influence of polymer modifications on the affinity to a target-
protein. The so called “final plot” in Figure 6a displays the titration of insulin solution with 
P(26)-1LL polymer. The peaks in the upper window represent the heat flow of the ongoing 
complexation reaction. This continues until only dilution effects of excessive polymer 
addition are detected within the last 3-4 peaks. The lower window represents the fit of the 
integrals according to the least squares method. The binding constants ranged from 4.68 × 105 
with P(26)-1LL to 9.53 × 106 M-1 with P(150) (Figure 6b).
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Figure 6a. MTC final plot of DEAPA(26)-(1)/insulin.
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48
An increase in the binding constant can be attained by two ways: First with a higher degree of 
amine substitution, leading to a higher charge density. The binding constant increased almost 
linearly (correlation coefficient ~0,998) for P(26), -(68) and -(150). Second is by the 
introduction of hydrophobic lactic acid side chains, which have to exceed a critical length to
influence the complexation of insulin significantly. A strong increase of Kbin to 7.54 × 106 M-1 
was seen when lactic acid grafting increased from (1LL) to (2LL), due to additional 
hydrophobic binding forces. It was not possible to investigate P(13) because of its weak 
complexation properties and P(26)-3LL due to its precipitation tendency. 
For comparison, the binding constant for soluble insulin to crystals of cationic 
protamine/insulin (0.27mg/100 I.U.) at pH 7.5 is (buffer dependent) 15.5 - 37.7 × 105 M-1 (38) 
and the strong binding of the two first hexacoordinated zinc atoms per insulin hexamer is in 
the magnitude of 1.9 - 4.7 × 106 M-1 (39), documenting a substantial affinity of insulin to the 
DEAPA polymers. 
The calorimetric enthalpy change (∆H) measured in an ITC experiment is the total change in 
enthalpy for the whole system. That means exothermic or endothermic events can be 
associated with conformational change of the reactants, ionization of polar groups and 
interactions with the solvent. The determination of the true (intrinsic) enthalpy requires 
additional experiments in different solvents and should in this context not be discussed in 
detail. The driving force of complex formation is mainly the gain in entropy due to the 
liberation of the low molecular counterions. The derived entropy values for the complexation 
reactions ranged from 45 for P(26) to 255 kcal/mol for P(150). From a thermodynamic point 
of view, polyelectrolytes with stronger ionic groups and/or higher molecular masses are 
generally favored in complex formation (33). 
Another parameter directly obtained by ITC is the stoichiometry of the binding partners at the 
turning point of the isotherm. This stoichiometry cannot be directly compared with 
turbidimetry due to different physicochemical principles. The thermodynamic stoichiometry 
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of insulin/polymer was about two to three times higher than the molar ratios derived from 
turbidimetry (Table 2).  
2.4.5. Visualization of NC
Atomic force microscopy (AFM) is a microscopic technique which allows the imaging of NC 
formulations independent of their composition under wet (physiological) conditions. Using 
AFM, in contrast to the electron microscopy, samples can be measured without preparation or 
fixation. AFM is an excellent method for imaging soft and flexible objects with high 
resolutions, allowing determination of particles sizes and surface morphology on a nanometer 
scale resolution. For size determination, all NC within a representative scan area (25 × 25 µm) 
were evaluated individually (Table 2). These data can deviate from the results of PCS 
measurements for several reasons. First, interaction of soft and flexible polymer NC with the 
surface of the silicon support can cause artifacts. The individual particle analysis allows 
exclusion of such artifacts. 
In addition, the visualization and evaluation of NC enables us to investigate the stability of 
these particles. The morphology of spreaded surface films of the pure polymer solution 
exhibited a uniform appearance for all polymers. The polymers form globular structures with 
a high tendency to generate fractal structures. The size for the globuli ranged between 25nm 
for P(26) (Figure 10/B) and 38 nm for P(26)-2LL. The investigated polymer/insulin 
nanocomplexes showed average particle sizes between 274 nm (P(26)) and 434 nm (P(150)). 
These values are in excellent accordance with the results determined by PCS. A general 
overview of a NC distribution is seen in Figure 7 for P(26)/insulin. All particles were of round 
shape and stable; no tendency for agglomeration could be observed. Only the formulation of 
P(26)-3LL NC showed a very inhomogeneous particle distribution and the tendency of stack 
formation. In the case of P(26), two major sub-populations were observed.
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Figure 7.  Tapping mode AFM images: Overview of DEAPA(26)/insulin complexes:
(left) 10.0 µm and (right) 2.0 µm scale.
The smaller fraction had an average diameter of approx. 204 nm, and the larger fraction 
showed sizes between 300 nm and 400 nm. This feature also explains the differences in the 
size measurements between the used methods. The surface of the particle is very smooth, no 
breaks or cracks could be seen. 
A general problem with soft objectives like NC, even in the non-contact mode, is to obtain 
accurate height information. Often nanoparticles show a tendency to coalesce at the surface 
leading to significant height differences and very flat structures (40). Under our experimental 
conditions the NC exhibited a good aspect ratio between height and diameter (figure 8) which 
was confirmed by a cross-section of 2 µm and additional height measurements (figure 9). 
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Figure 8.  Three-dimensional structure of nanocomplexes.
Figure 9.  Cross-section for nanocomplexes from AFM line analysis.
A special technique of AFM is the so-called phase imaging mode measuring the material 
contrasts depending on the stiffness or elasticity of the object (41). Differing material 
properties are presented in different color intensities in images of insulin (a) and DEAPA 
polymers (b) as shown in Figure 10. More rigid materials show a brighter image than softer 
materials. In the case of P(26), different bright areas within the particles could be observed 
(Figure 10/c). The areas were very small with a size between 5 and 20 nm and can be 
discussed as a distribution of polymer/insulin nanostructures with different compositions. 
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Figure 10.  AFM phase mode: (A) Insulin, (B) DEAPA(26) polymer, (C) NC of A/B. AFM 
Tapping mode: (D) surface structure of C.
Brighter areas consist of domains with a higher content of insulin and were more rigid, while 
darker areas consist of regions with higher polymer content. The results of the AFM 
investigation are compatible with a spheroidal shape for the nanocomplexes and an entangled 
internal structure for insulin and DEAPA polymers.
A B
C D
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2.5. Conclusion  
A series of polymers was synthesized and characterized exhibiting a comb-like structure. The 
variation of hydrophobicity by lactic acid side chain grafting and charged groups, at 
physiological pH, resulted in branched polyesters with a positively charged backbone offering 
multiple binding sites for the preparation of colloidal nano-carrier systems. It was possible to 
manipulate the hydrophilic-hydrophobic balance of these polyesters by factors such as 
molecular weight, PLLA chain lengths and degree of amine-substitution. Water solubility of 
these polymers allowed the self-assembling of small NC with narrow size distribution without 
any mechanic emulsification procedures and without the use of surfactants. 
Insulin was complexed to a high extent resulting in uniform particles with an entangled 
structure. The increase in binding affinity, drug loading, zeta potential and the decrease in size 
could be correlated with a higher substitution degree of DEAPA groups and a higher lactic 
acid grafting of the backbone. The possibility of designing the polymer structure in a rational 
manner may provide significant advantage for generating nanocarriers for mucosal drug 
delivery. The potential of these NC for nasal delivery of insulin with in-vivo models is 
currently under investigation in our laboratory.
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3.1. Abstract
Purpose: Bioavailability and local tolerability of insulin containing nano-complexes from 
amine-modified poly(vinyl alcohol)-graft-poly(L-lactide) were studied in rats after nasal 
application. Histology of the nasal epithelium was investigated to verify the integrity of the 
nasal mucosa. Methods: Nano-complexes (NC) were prepared by spontaneous self-assembly 
of insulin and the water-soluble amphiphilic polymer. Changes in blood glucose and insulin 
blood concentration were monitored in anaesthetized rats using a glucose meter and ELISA 
respectively. Histological sections of the nasal cavity were examined after H&E staining by 
light microscopy. Results: NC reduced blood glucose level in fasted healthy rats by 20% after 
50-80 min and in streptozotocin induced diabetic rats by 30% within 75-95 min compared to 
basal levels. In both animal models significant concentrations of human insulin were detected, 
with relative bioavailabilities Frel of 2.8 up to 8.3 %. The more hydrophobic, lactic acid 
grafted polyester were more effective at a threefold higher polymer concentration, increasing 
the relative bioavailability Frel of a 5 I.U./kg dose from 2.8 to 5.7 %. Histological examination 
of the nasal mucosa after 4h showed no signs of toxicity at the site of nasal administration. 
Conclusions: These results demonstrate that the NC significantly enhanced insulin absorption, 
suggesting that amphiphilic biodegradable comb-structured polymers could be a promising 
approach for nasal peptide delivery.
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3.2. Introduction
 Recent progress in biotechnology led to an enormous growth in the number of peptide and 
protein drugs which usually require parenteral administration to become therapeutically useful 
(1,2). Non-parenteral administration across mucosal surfaces, e.g. rectal, buccal, vaginal, 
nasal and pulmonary epithelia have been considered as alternative routes of application to 
replace parenteral injections (3,4).  Among them, nasal delivery of peptides attracted strong 
interest due to its favorable biopharmaceutical properties. The structure of the nasal 
epithelium, its high blood perfusion and lower detrimental enzyme concentrations may result 
in higher bioavailabilities as compared to oral administration (5). Nasal drug administration 
facilitates self-medication thus improving patient compliance. Protein and peptide drugs 
show, however, frequently low and variable bioavailabilities after nasal administration e.g. for 
insulin <1% (6). Therefore, nasal insulin therapy necessitates co-administration of absorption 
enhancers such as surfactants, bile salts, fusidic acid derivatives, medium-chain fatty acids, 
chelators or enzyme inhibitors to increase absorption and hence bioavailability (7,8). 
Although these absorption enhancers significantly increase transmucosal peptide transport, 
local tolerability and safety concerns, related to membrane damage, ciliary toxicity, mucus 
discharge and epithelial disruption need to be overcome (9). 
Consequently, the design of appropriate peptide carrier systems avoiding harmful additives 
has become a topic of intensive research. Nanoscale colloidal carriers from hydrophilic and
biocompatible polymers, such as chitosan (10), were found to be useful for nasal vaccine (11)
and insulin delivery (12) without employing additional penetration enhancers. Not only size 
and surface properties but also the polymer composition and architecture affected functional 
properties of nano-carriers such as transport of macromolecules across biological surfaces. In 
general nanoscale dimensions favor transport of particles across mucosal epithelia (13,14).
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Moreover, nano-carriers with bioadhesive properties, e.g. NP coated with Carbopol, 
prevented rapid nasal clearance (15). Increasing residence time in the nasal cavity, was 
thought to improve drug absorption (16,17). Through design of polymer properties,
nanoparticle characteristics can be manipulated such as hydrophilicity and surface charge.
Especially polycations like poly(L-lysine), protamine, poly(ethylene imine), chitosan and 
dextran derivatives seem to increase mucosal permeability (18-20). The combination of 
enhancing properties, mediated through cationic surfaces charges, with the formation of
nanoparticulate carriers was realized by encapsulating insulin into chitosan NP by ionotropic 
gelation, which yielded a significant blood glucose reduction in rabbits after nasal 
administration (21). 
In an attempt to combine different enhancer principles, namely amphiphilicity, cationic 
charges and bioadhesion into one macromolecule, we studied water-soluble amine-modified 
polyesters, namely poly(vinyl 3-(diethyl)propylcarbamate-co-vinyl acetate-co-vinyl alcohol)-
as cationic backbone and the corresponding graft-polyesters with short (L-lactic acid) side 
chains for their potential to form insulin-nano-complexes by spontaneous self-assembly (22). 
The objective of the present work was to evaluate two formulations of NC, composed of the 
polymers P(26) and P(26)-2LL, as a novel nasal delivery system for insulin in a rat model and 
to explore the influence of the different polymeric structures on absorption enhancement.
3.3. Materials and Methods
3.3.1. Materials
 Polymers were synthesized and characterized as previously described (20). As abbreviation 
for the polymers we use: P(X)-YLL. P(26) carried 26 amino-groups per PVA molecule 
(DP=300). P(26)-2LL had additional 48 short lactide chains per backbone with an average 
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chain length of about three lactic acid units. Human recombinant insulin (26.2 I.U./mg) was a 
gift from Aventis Pharma AG (Germany).
3.3.2. Nanocomplexes Preparation
Insulin stock solutions with concentrations of 4.3, 5.7 and 11.4 mg/ml for 4.0, 5.0 and 10 
I.U./kg doses respectively were prepared in two steps: 1. The insulin powder was dissolved in 
87% (V/V) 1.15x10-2 N-HCl in 10 ml-Pyrex tubes. 2. 13% (V/V) of 0.1 N-
Tris(hydroxymethyl)amino methane solution was added resulting in a clear Tris-buffer 
solution with low ionic strength (I=0.01) and pH 7.4. Polymer stock solutions in 
concentrations from 2.15 mg/ml for P(26) and 7.30, 9.70 respectively 29.70 mg/ml for P(26)-
2LL were prepared in Tris-buffer. An equal volume of the filtered stock solutions of insulin 
and polymer were mixed resulting in defined ratios (Table 1) of insulin/polymer in the final 
NC-solution as previously described (22). The colloidal polymer-insulin complexes were 
formed after mixing of the aqueous buffer solutions containing insulin and polymer by 
spontaneous self-assembly. 
3.3.3. Animal Preparation and Dosing 
Male Wistar rats of about 250g (Charles-River Wiga, Germany) were fasted overnight with 
free access to water. Diabetic rats were obtained after streptozotocin treatment (55 mg/kg) and 
included into the experiment when blood glucose levels exceeded 250 mg/dl. Rats were 
anesthetized by ether inhalation for ~ 2 min in a sealed glass container followed by 
intraperitoneal injection of avertin. Preparation of avertin: Stock solution was prepared with 
25.0g 2,2,2-tribromoethanol in 15.5 ml tert-amyl-alcohol (Sigma-Aldrich, Germany) mixed 
for 12h in a dark bottle at room temperature. Working solution was made fresh before use of 
0.5 ml Avertin stock added with 39.5 ml 0,9% NaCl (Braun Melsungen, Germany) and 
filtered through a 0.2µm filter. The animals were dosed with 10 µl/g body weight by 
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intraperitoneal injection and remained anesthetized for 60-90 min (healthy) and 30-40 min 
(diabetic) in a supine position, ensuring that the administered dose was not swallowed or 
sniffed during the resorption period. Nasal delivery took place 15-20 min after injection of 
Avertin. NC suspensions (~ 20µl) were carefully delivered to the right nostril only, using a 
Hamilton syringe with an attached polyethylene tube, which was inserted about 0.5 cm into 
the nostril. The animal study was conducted according to the principles outlined in the “Guide 
for the Care and Use of Laboratory Animal Resources” (National Academy Press, 
Washington) and had received approval by the Animal Review Committee at the local 
authorities.
3.3.4. Glucose and Insulin Measurements 
Blood glucose levels were directly measured in blood collected from the tip of the rat tail 
using a glucose meter (Glucometer Elite, Bayer Corp., Germany). Blood samples (~ 200µl) 
for insulin determination were collected in Microvettes CB300 (Sarstedt, Germany) at the 
same time points of -10 and -5 min before formulation application and at various time 
intervals up to 4h post administration. The glucose content was calculated as a percentage of 
the mean value of the first three measurements for each animal. The values of the blood 
glucose baselines were in the range of 75-105 mg/dl for healthy rats and 350-500 mg/dl for 
diabetic rats. The quantitative determination of human insulin in serum was carried out using 
an enzyme immunoassay ELISA (Cat. EIA-2935, DRG Instruments GmbH, Germany), which 
exhibited no cross-reactivity to rat insulin. 
3.3.5. Analysis of Data 
The areas under the curve (AUC) for the insulin concentration against time respective the 
glucose percent against time were calculated for the various groups using the trapezoidal 
method. Statistical analysis was performed by one-way analysis of variances (ANOVA) using 
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the Origin 6.0 software (OriginLab, USA). Throughout the level of significance was chosen 
as p < 0.05.
3.3.6. Histological studies 
From the healthy rats three animals per group were randomly selected. The animals were 
decapitated, the mandible, brain and excess soft tissue removed and the residuals were fixated 
in formalin solution and decalcified in 10% Titriplex III solution adjusted to pH 7.2 (Merck 
KG, Germany) for three weeks. All regions were processed through to Paraplast embedding 
(Carl Roth GmbH, Germany) using routine histological methods. Sections were cut serially at 
7µm thickness with a Reichert-Jung Biocut 2030, mounted and stained with haematoxylin and 
eosin. According to the method by Thomas N.W. (24) the cross-sections of the nasal cavity 
were examined with the light microscope (Olympus BHZ). 
3.4. Results and discussion
3.4.1 Non Diabetic Rats
Previously we described nanocomplex (NC) formation between insulin and amphiphilic 
cationic charge-containing biodegradable copolyesters composed of a hydrophilic PVA 
backbone grafted with short hydrophobic lactic acid groups (22). From a range of compounds 
we selected two polymers, the charge modified backbone P(26) and a corresponding graft-
polyester P(26)-2LL to evaluate the influence of PLA grafting. Insulin NC revealed interesting 
properties for a nasal peptide delivery system: positive zeta potential  ~ +20 mV, small 
particle sizes in the range of 200-450 nm, high insulin loading efficiency and bioadhesive 
attributes as demonstrated for NP of DEAPA-PVA-g-PLGA (25). The dose for insulin was 
selected based on the expected pharmacological effect and the respective route of 
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administration. Polymer concentrations ranged from 0.076 to 0.973 mg/kg body weight and 
reflected optimal polymer/insulin ratios from systematic investigations of the complexation 
process (Table 1).
Formulation Insulin
single
dose (IU)a.
Insulin
conc.
(IU/kg)
Polymer
conc.
(mg/kg)
Particle size
(mean ± SD) 
(nm)
Zeta 
potential
(mV)
Mass 
ratio
(Ins/Poly)
Group of healthy rats
INS Sol s.c. 0.125 0.5 - - - -
INS Sol i.n. 1.0 4.0 - - - -
INS/P(26) NC 1.0 4.0 0.076 394 ± 61 17.7 ± 2.7 2.0 : 1.0
INS/P(26)-2LL NC 1.0 4.0 0.260 250 ± 39 18.8 ± 3.3 1.0 : 1.7
Group of diabetic rats
INS Sol s.c. 0.1875 0.75 - - -
INS/P(26)-2LL NC 1.25 5.0 0.324 275 ± 52 18.4 ± 3.4 1.0 : 1.7
INS/P(26)-2LL NC 1.25 5.0 0.973 448 ± 25 5.0 ± 1.1 1.0 : 5.1
INS/P(26)-2LL NC 2.50 10 0.649 290 ± 62 22.9 ± 2.5 1.0 : 1.7
a based on an average of 250 g body weight per animal
Table 1. Characterization of administered solutions/nanocomplexes
Evaluation of these NC in an animal model is one prerequisite for studying these nasal 
delivery system in human clinical trials. Therefore, Wistar rats were used as well established 
animal model for nasal absorption studies. First we studied the absorption enhancing 
properties of both formulations after nasal application in a non-diabetic, fasted rat model. 
Figure 1 shows the blood glucose time profiles, figure 2 the insulin time curves and table 2 
the corresponding pharmacokinetic and pharmacodynamic parameters: cmax/min, Tmax/min, AUC 
and Frel/dyn.
The pharmacodynamic effect of insulin NC versus a subcutaneous reference is shown in fig. 
1. In the control group receiving a buffered solution with 4.0 IU/kg insulin intranasally only a 
slight decrease in blood glucose concentration was observed in accordance with the literature 
(9).
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Figure 1. Blood glucose reduction in healthy rats: ∆ Insulin s.c. with 0,5 IU/kg, −−ο−− 
NC composed of P(26)-2LLwith 4,0 IU/kg insulin, Χ NC composed of P(26) with 4,0 
IU/kg insulin,  −−   −− control solution with 4,0 IU/kg insulin in buffer.
Stable glucose concentration (95-105%) in this group over the experimental period of 240 
min indicated that the animals were not stressed by anesthesia and blood sampling 
procedures. Stress could provoke an increase of blood glucose levels due to hormonal effects. 
The subcutaneous reference of 0.5 IU/kg insulin yielded a Cmin 56% of the basal glucose 
concentration after 72 min. Corresponding insulin data in figure 2 showed values of Cmax and 
Tmax of about 79 µIU/ml and 18 min respectively. The glucose profiles, which reflected 
insulin action, followed the plasma insulin levels with a slight delay. The AUC values 
resulting from s.c. application  were used as benchmark to calculate the relative 
bioavailability Fdyn/rel.
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Figure 2. Plasma insulin from healthy rats: ∆ Insulin s.c. with 0,5 IU/kg, −−ο−− NC 
composed of P(26)-2LLwith 4,0 IU/kg insulin, Χ NC composed of P(26) with 4,0 IU/kg 
insulin,  −−   −− control solution with 4,0 IU/kg insulin in buffer.
Both the NC of insulin/P(26)-2LL and - P(26) increased the insulin plasma level up to 29.1 ±
5.1 µIU/ml or 35.7 ± 13.8 µIU/ml respectively about 10-15 minutes after nasal instillation. 
The administration of insulin solution without polymer (control group) resulted in a low 
plasma level of 5.9 ± 2.4 µIU/ml. The partially elevated insulin absorption in the control 
group could be due to an effect of the anesthetic agent as suggested by Illum and Mayor (26).
It was not possible to dose fully conscious rats as control in order to investigate the effects of 
avertin, because non-anaesthetized rats, as obligatory nose breathers, sneeze vigorously and 
nasally administered solutions are discharged from the nasal cavity. Therefore, relative 
bioavailabilities between the different treatment groups were assessed, with all animals 
anesthetized in the same way. Those treated with insulin NC exhibited elevated insulin levels 
with Frel 5.84 ± 0.9% for insulin/P(26)-2LL and 8.32 ± 1.2% for insulin/P(26), in comparison 
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to the insulin control group with Frel 2.82 ± 1.0%. These findings suggest that the changes in 
blood glucose concentrations are a direct consequence of elevated insulin blood levels and not 
a decrease e.g. due to other hormonal counter regulatory effects. The AUC values for both 
types of NC were significantly different compared to the control group (P < 0.05). The 
observation that the insulin control group exhibited no glucose change despite slightly 
elevated human insulin levels could be due to an auto regulation effect observed in healthy 
rats: small amounts of absorbed exogenous insulin depresses the endogenous secretion of 
insulin by β-cells, and consequently the amount of exogenous insulin is not sufficient to affect 
glycaemia (27). Otherwise the exogenous insulin concentration in the NC treated groups was 
too high for compensation by regulatory mechanism. A correlation between applied insulin 
dose and insulin plasma level requires additional experiments and is beyond the scope of this 
investigation. 
Improved insulin absorption after nasal administration of NC formulations was supported by 
the corresponding glucose data: The decrease in plasma glucose levels in both groups treated 
with nasally applied NC was significantly different (P < 0.05) from that induced by the insulin 
control solution. Insulin NC with P(26) lowered the basal glucose concentration about 17% 
within 52 min and the NC with insulin/P(26)-2LL about 22% after 82 min respectively. The 
decrease lasted up to 180 min since values close to basal levels were recorded at the last 
measuring time point at 240 min. 
The relative bioavailability Fdyn for insulin/P(26)-2LL was in the range of 7.7 % and for 
insulin/P(26) about 6.38 % in contrast to 0.96% for the control group. This reflects a 
significant and distinctive metabolic response as consequence of insulin NC application. 
While the pharmacological difference between both NC groups is not significant (P <0.05), 
the glucose-time curve exhibited a differential course: The glucose minimum for P(26)-2LL 
NC is more clearly pronounced and lasted for longer time than the NC composed of 
insulin/P(26) indicating improved properties for the more hydrophobic polymers.
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Analysis of Pharmacodynamics 
Formulation n Tmin
(min)
Cmin
(% basal 
glucose)
AUC0-240min
(% x min)
Fdyn
(%)f
INS Sol s.c.a 4 72.5 ± 15.0 56.3 ± 4.2 4488 ± 795 100.0 ± 17.7
INS Sol i.n.b 4 107.5 ± 56.2 96.6 ± 2.0 348 ± 72 0.96 ± 0.2
INS-DEAPA26c 4 52.5 ± 20.6*/- 83.5 ± 2.1*/- 2292 ± 470 6.38 ± 1.3*/-
INS-DEAPA26/2d 4 82.5 ± 28.7*/- 78.2 ± 4.1*/- 2770 ± 324 7.72 ± 0.9*/-
one-way ANOVAe P > 0.05 P > 0.05
Analysis of Pharmacokinetics 
Formulation n Tmax
(min)
Cmax
(µIU/ml)
AUC0-240min
(µIU/ml x min)
Frel
(%)f
INS Sol s.c.a 4 17.5 ± 9.6 78.7 ± 37.1 4861 ± 669 100.0 ± 13.7
INS Sol i.n.b 4 37.5 ± 55.5 5.9 ± 2.4 1098 ± 393 2.82 ± 1.0
INS-DEAPA26c 4 8.8 ± 2.5*/- 35.7 ± 13.8*/- 3237 ± 464 8.32 ± 1.2*/**
INS-DEAPA26/2d 4 15.0 ± 5.8*/- 29.1 ± 5.1*/- 2270 ± 360 5.84 ± 0.9*/**
one-way ANOVAe P > 0.05 P > 0.05
Table II. The Pharmacokinetics and Pharmacodynamics of insulin in a healthy rat model
a Insulin solution, administered by subcutaneous injection
b
 Insulin solution administered intranasally
c
 Insulin/P(26)-Polymer nanocomplexes administered intranasally
d
 Insulin/P(26)-2LL-Polymer nanocomplexes administered intranasally
e Significance level of comparisons made between treated and control groups(*/), respective 
  between nasally treated groups (/**), denoted when significant different otherwise (-) 
 
f Calculation according to formula: 100
..
.. ×
×
×
=
Testcs
csTest
DosisAUC
DosisAUC
F
3.4.2. Diabetic Rats
In diabetic rats insulin deficiency causes severe changes in metabolism amongst others, a 
reduction in liver protein synthesis, decreased activity of the sympathetic nervous system, 
dehydration, glycosuria and osmotic diuresis (28,29). Thus, streptozotocin-diabetic rats
showed a different response profile to environmental stress factors (30). For instance, duration 
of anesthesia is significantly reduced and variability of blood glucose levels is increased. As 
this was observed for different control groups especially after 120 min, the pharmacological 
data were evaluated only for a timeframe up to 120 min. 
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After establishing the penetration enhancement of P(26)-2LL-insulin NC we investigated in 
more detail formulation aspects, varying polymer and insulin concentration in the diabetic rat 
model. Figure 3 shows the glucose time courses, figure 4 the insulin time curves and table 3 
the corresponding pharmacokinetic and pharmacodynamic parameters: cmax/min, Tmax/min, AUC 
and Frel/dyn.
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Figure 3. Blood glucose reduction in diabetic rats. ∆ Insulin s.c. with 0,75 IU/kg, Option 
1: −−   −− NC composed of P(26)-2LL (1.7 : 1.0 m/m polymer/insulin) with 5,0 IU/kg insulin, 
Option 2: −−ο−− NC composed of P(26)-2LL (5.1 : 1.0 m/m) with 5,0 IU/kg insulin, Option 3: 
Χ NC composed of P(26)-2LL (1.7 : 1.0 m/m) with 10,0 IU/kg insulin, −−θ−− control 
solution with 5,0 IU/kg insulin in buffer.
We administered an insulin dose of 5.0 IU/kg keeping the polymer concentration constant at a 
mass ratio of 1:1.7 insulin/polymer (Option 1). At a constant insulin dose we increased the 
polymer concentration threefold to a 1:5.1 mass ratio, to probe if an increase in insulin 
bioavailability could be related to the amount of instilled polymer (Option 2). Finally, we 
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increased concentration of NC in the suspension reaching a dose of 10.0 IU/kg at a constant 
1:1.7 mass ratio (Option 3). After subcutaneous administration of insulin solution (0.75 
IU/kg) an immediate and distinctive decrease of glycemia was observed (figure 3).
The AUC0-120min values for glucose/time and the AUC0-240min for insulin/time resulting from 
s.c. application were used as reference to calculate the bioavailabilities Fdyn/rel. The NC of 
P(26)-2LL-insulin according to option 1 caused a clear blood glucose reduction as expected. 
The minimum was achieved after 93 min with 20% decrease of the blood glucose basal levels 
and a relative bioavailability Fdyn of 8.5 %. 
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Figure 4. Plasma insulin from diabetic rats: ∆ Insulin s.c. with 0,75 IU/kg, ⋅⋅⋅Χ⋅⋅⋅ NC 
composed of P(26)-2LL with 10,0 IU/kg insulin (1.7:1.0), ⋅−⋅ο⋅−⋅ NC composed of P(26)-2LL 
with 5,0 IU/kg insulin (5.1:1.0), −−   −− NC composed of P(26)-2LL with 5,0 IU/kg insulin 
(1.7:1.0), θ control solution with 10,0 IU/kg insulin in buffer.
Figure 4 depicts the corresponding rapid increase in human insulin levels for option 1 up to 18 
µIU/ml within 14 min, corresponding to a bioavailability Frel  about 2.8 %. The strongest 
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decrease in blood glucose was achieved with option 2, containing a threefold higher polymer 
concentration. The formulation according to option 2 exhibited a fast onset of insulin action in 
the first 50 min, which is comparable to the s.c. application (figure 3). The blood glucose 
decrease reached a maximum of 30% of the basal values after 75 min. That correlates with the 
fast increasing blood insulin concentration to 30 µIU/ml after 14 min (figure 4).
Analysis of Pharmacodynamics 
Formulation n Tmin
(min)
Cmin
(% basal 
glucose)
AUC0-120min
(% x min)
Fdyn
(%)f
INS Sol s.c.a 4 140.0 ± 34.6 50.7 ± 10.2 3576 ± 581 100.0 ± 16.3
INS Sol i.n. 4 110.0 ± 663 87.7 ± 5.8 487 ± 93 2.04 ± 0.4
5.0 I.U. with 1.7b 4 93.3 ± 23.1-/- 80.3 ± 6.1*/- 2038 ± 261 8.54 ± 1.1*/**
5.0 I.U with 5.1c 4 75.0 ± 33.2-/- 70.2 ± 4.2*/- 2803 ± 213 11.76 ± 0.9*/**
10.0 I.U. with 1.7d 4 160.0 ± 34.6-/** 68.8 ± 3.1*/- 2703 ± 401 5.67 ± 0.1*/**
one-way ANOVAe P > 0.05 P > 0.05
Analysis of Pharmacokinetics
Formulation n Tmax
(min)
Cmax
(µIU/ml)
AUC0-240min
(µIU/ml x min)
Frel
(%)f
INS Sol s.c.a 3 16.7 ± 11.5 67.5 ± 23.9 6456 ± 1063 100.0 ± 16.5
INS Sol i.n. 4 21.3 ± 20.1 3.8 ± 2.9 261 ± 178 0.30 ± 0.2
5.0 I.U. with 1.7b 4 13.8 ± 7.5*/- 17.9 ± 6.9*/- 1194 ± 521 2.77 ± 1.2*/**
5.0 I.U with 5.1c 4 13.8 ± 7.5*/- 30.0 ± 10.6*/- 2438 ± 476 5.67 ± 1.1*/-
10.0 I.U. with 1.7d 4 16.7 ± 5.8*/** 47.0 ± 29.9*/** 4533 ± 2201 5.27 ± 2.6*/-
one-way ANOVAe P > 0.05 P > 0.05
Table III. The Pharmacokinetics and Pharmacodynamics of insulin in a diabetic rat model
a Insulin solution administered by subcutaneous injection
b-d
 Insulin/P(26)-2LL-Polymer nanocomplexes administered intranasally 
    ( Option 1 b, Option 2 c, Option 3 d)
e Significance level of comparisons made between treated and control groups(*/), respective 
  between nasally treated groups (/**), denoted when significant different otherwise (-) 
f Calculation according to formula: 100
..
.. ×
×
×
=
Testcs
csTest
DosisAUC
DosisAUC
F
The resulting bioavailabilities with Fdyn 11.8 % and Frel 5.67 % were significantly higher than 
for option 1 (p <0.05). Then we evaluated the effect of increasing the dose to 10.0 IU/kg at a 
higher concentration not increasing the volume. After nasal administration the blood insulin 
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concentrations rise to 47 µIU/ml after 17 min. The bioavailability Frel with 5.3 % was 
significantly increased compared to option 1. This increase could be explained due to a higher 
local NC concentration, leading to a higher concentration gradient at the site of absorption. 
Furthermore the absolute polymer concentration was two-fold higher compared to option 1.
Systematic investigations of the complex assembly demonstrated that a defined ratio of both 
binding partners is necessary for optimal NC formation (22). For insulin/P(26)-2LL NC the 
optimal ratio is 1.0 insulin to 1.7 polymer (m/m) (see table 1). A threefold increase of the ratio 
for P(26)-2LL NC from 1.7 to 5.1 increases the average complex size from 275 to 448 nm and 
decreases the zetapotential from about +18.4 to  +5.0 mV to (table 1). Increasing the ratio
obviously reduces specific advantages of nanocarriers, however, the bioavailability of 5.0 I.U. 
insulin as a single dose increases. We assume the spontaneous occurrence of complex 
rearrangement processes and an overall increase in free polymer concentration especially for 
higher polymer ratios (22). Increased bioavailability could therefore be likely related to a 
higher polymer concentration, resulting in more direct interaction of polymer and epithelium, 
rather than the nanoparticle character of the carrier. Similar observations were published by 
Dyer and Illum et al. (31). They reported insulin-chitosan solution to be significantly more 
effective than the NP formulation, and they also observed an influence of chitosan 
concentration (20). Other researchers demonstrate the superiority of chitosan-insulin NP 
against solutions (12), but also discuss whether the effect of the nanoparticulate system is 
more likely due to an interaction of chitosan to epithelial membranes, in terms of bioadhesion 
and transient opening of the tight junctions (32). 
It is generally accepted that two major pathways are available for transport of drugs across the 
epithelial membrane, namely the paracellular and transcellular route. The tight junctions can 
be influenced by interaction of the epithelia with polymeric materials and actually we are 
investigating on the caco-2 cell line if the cationic poly(vinyl 3-(diethyl amino) 
propylcarbamate-co-vinyl acetate-co-vinyl alcohol)-graft-poly(L-lactide) can interact with the 
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junctional complex, temporarily opening the paracellular transport pathway as reported for 
chitosan (32). 
3.4.3. Histological Studies
Increased absorption of peptides after nasal application has been reported in a number of 
studies after co-administration with absorption enhancers such as: surfactants, including bile 
salts and their derivatives, chelators and enzyme inhibitors. Many absorption enhancers are
irritating to mucous membranes and the histological effects of some agents on nasal mucosa 
have been reported. Even after a single application of formulations containing enhancer like 
laureth-9 (1% w/v) cellular erosion, cell-cell separation, dense mucous coating and 
subsequent reduction of epithelial height from rat nasal epithelium were observed within five 
minutes after nasal application (9). Therefore, it is desirable to evaluate histopathological 
effects. The anatomical division of the rat nasal cavity by the midline septum enables the 
assessment of histopathological effects by direct comparison of the treated and untreated side. 
Errors due to inter-animal variability and tissue sampling are thus minimized. The major 
structural features in each region of the rat nasal cavity, including the septum and the 
turbinates, could be identified in the overview micrographs (figure 5a). Especially the area of 
the nasal septum, which consists of respiratory epithelium, is of interest, because it is the 
projected deposition site for the administered dose. 
The magnification in figure 5a shows the typical anatomy of the septum: cartilage, covered by 
ciliated pseudo stratified columnar epithelium, populated with goblet cells. A basic 
requirement, for comparability and reproducibility of the histological and pharmacological 
results is that the administered dose is deposited on a restricted area. For small volumes of 20-
30 µl per dose no leakage via the septal window in more posterior regions was reported.
Volumes in this range are known to be retained exclusively at the site of application (9). It 
was necessary to insert the tubing in the rat nostril 5 min prior to the application of the 
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solutions. This procedure allowed the rats to acclimate on hampered breathing and prevented 
loss of the administered dose through sniff or exhale from the nasal cavity.
Figure 5. Photomicrographs of vertical sections through the anterior rat nasal cavity showing 
two sides of the nasal septum 4h after application of 20-25 microliter of insulin solution into 
the right side (R). Normal respiratory epithelium populated with goblet cells covers the 
undosed left side (L) in each case. Treated tissue on the right side can be compared with 
untreated tissue on the left of the septum; epithelium thickness on the right side was 134 ± 14 
micrometer and on the left side 137 ±15 micrometer (n.s.). a.) a section overview from control 
group (insulin s.c.), magnification x 20. b-d.) represents the septum region from (a) indicated 
by the black rectangle, magnification x 100 b.) nasal insulin application without polymer 
(non-polymeric control) c.) NC composed of insulin and P(26)-2LL d.) NC composed of 
insulin and P(26) b.-d.) show no clear difference of the epithelial lining between dosed side 
and untreated side.
The rat experiments were performed without surgical procedures like tracheotomy or 
esophagus ligation to simulate, as far as possible, realistic conditions. This animal model 
R
L
a. b.
c. d.
L R
L L
R
R
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saves certainly the potential danger of aspiration of a part of the dose volume. However, the 
supine position of the animal, as well as the small volume, would contribute to a restricted 
distribution and a reproducible disposition at the site of absorption.
The histological tissue preparation was performed at the end of the blood measurements after 
4h, so that toxicological effects of longer lasting adhesion of polymer residues were taken in 
account. In each animal treated with NC or insulin control solution, all regions of the dosed 
side of the cavity were covered by an intact, undamaged epithelium layer, comparable to that 
observed in the sections of the non dosed side. On the dosed side none epithelial disruption 
has occurred on septal and nasoturbinate surfaces neither for insulin/P(26)-2LL NC (figure 5c) 
nor for insulin/P(26) NC (figure 5d). Moreover, the treated and untreated side of the nasal 
cavity in each cross-section matched each other with respect to the height of the respiratory 
epithelia. Repeated dosing and recovery studies are necessary to establish the full 
toxicological implications for a chronic administration. However, none acute adverse effects 
were registered in our single dose experiment for both NC preparations.
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3.5. Conclusion
As an alternative application route for insulin, the intra-nasal administration along with 
pulmonary delivery represents one of the most promising options for diabetic patients. The 
commercial exploitation of nasal insulin delivery depends on the development of new and 
safe enhancers, increasing the absorption and hence bioavailability. Here we report on the 
feasibility for two types of Insulin NC from a novel class of amphiphilic comb-like polyesters 
demonstrating enhanced insulin absorption across rat nasal mucosa. These data indicated that
amphiphilic NC with grafted lactic acid side chains were superior to more hydrophilic 
backbones. The relative effect availabilities (glucose) and bioavailability (insulin) suggest that 
significant enhancement factors can be attained using NC. Both nanocomplex preparations 
were shown to be non-toxic after a single nasal administration. The effect of lowering blood 
glucose levels observed in healthy rats could be reproduced in diabetic rats. Therefore, NC on 
the basis of insulin/P(26)-2LL NC may present a promising delivery system for peptides 
enhancing mucosal absorption. Further work is warranted to elucidate the enhancer 
mechanism.
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Chapter 4
Nanosized insulin-carrier based on amine-modified graft polyesters: 
Protection from enzymatic degradation, interaction with Caco-2 cell 
monolayers, peptide transport and cytotoxicity.
Publication in preparation 
(for European Journal of Pharmaceutics and Biopharmaceutics)
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4.1. Abstract
PURPOSE: Non parenteral insulin delivery via the gastrointestinal tract faces serious hurdles
in form of epithelial barriers and enzymatic degradation. Here we investigated novel insulin 
containing nano-complexes (NC) and –particles (NP) based on amine modified comb-like 
polyesters to overcome these barriers. METHODS: Trypsinic insulin degradation on NC and 
surface tension measurements on polymer solutions were performed. The interaction with
enterocyte-like Caco-2 cells in terms of cytotoxicity, transport through and uptake in the cell 
layers was evaluated by measuring transepithelial electrical resistance (TEER), release of 
lactate dehydrogenase (LDH), confocal laser scanning microscopy (CLSM) and transport 
studies. RESULTS: The protection capacity of nanocomplexes and their interaction with 
Caco-2 cells varied strongly as a function of lactide-grafting. With increasing lactide grafting
(P(26) < P(26)-1LL < P(26)-2LL) NC protected more than 95% of a 1,0 mg/ml insulin NC 
dispersion against trypsinic degradation. Insulin transport and layer uptake increased with 
higher L-lactid grafting. About 25% of a 1,25 mg/ml TRITC insulin NC dispersion with 
P(26)-2LL was recovered in the layer after 90 min, also visualized by CLSM. Accompanied by 
a concentration dependent cytotoxicity profile with elevated LDH release and decreased 
TEER values. The cytotoxicity correlates with the surfactant like character of the polymers, 
decreasing the surface tension to 45 mN/m for the amphiphilic P(26)-2LL. Nevertheless, the 
observed TEER decrease was reversible after 20 hours. CONCLUSIONS: These results 
demonstrate that the NC protect insulin and enhanced its absorption, suggesting that 
amphiphilic biodegradable comb-polymers offer a promising approach to overcome intestinal 
barriers.
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4.2. Introduction
Non-parenteral administration of peptide drugs, like insulin for the treatment of diabetes 
mellitus, remains a great challenge to pharmaceutical research. To circumvent the tedious
injection regime of insulin therapy, several attempts have been made to exploit mucosal 
surfaces, especially the nasal, pulmonary and oral mucosa, for the delivery of macromolecules
(1,2). Of these routes peroral administration would be the most desirable on a long term basis. 
However, enzymatic degradation by proteolytic enzymes and a low absorption rate (< 1.0%) 
over the gastrointestinal mucosa limits its relative bioavailability (3). Numerous strategies 
have been devised to enhance insulin absorption (4,5). Most often these strategies have 
focused at addressing one of the barriers to intestinal absorption, either the epithelial cell layer 
or the digestive enzymes. These include the co-administration of insulin with penetration 
enhancers and/or protease inhibitors, enteric coatings, colloidal drug carriers, such as 
nanoparticles and liposomes and chemically modification of insulin by covalent attachement 
of amphiphilic oligomers to increase its lipophilicity (6). Especially particles in the nanosize 
range, based on biodegradable and mucoadhesive polymers, are of particular interest, as they 
provide protection of sensitive proteins against enzymatic degradation and prolong intestinal 
residence time (7). Their transport however, across the intestinal barrier is controversially 
discussed. Uptake can occur not only via micro-fold (M)-cells, highly specialized epithelial 
cells in the Peyer’s patches, and isolated follicles of the gut associated lymphoid tissue 
(GALT), but also across the apical membrane of enterocytes (8). Non-covalent complexes 
formed between hydrophilic carrier molecules and insulin can induce partial and reversible 
unfolding of the insulin molecule, facilitating permeability by passive transcellular diffusion 
across cell membranes due to the increased flexibility and lipophilicity, before dissociation of 
the complex beyond the epithelial cell (9). As a new approach to non-parenteral insulin 
delivery, biodegradable nanocomplexes composed of insulin and poly[(vinyl-3-
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(diethylamino)-propylcarbamate-co-(vinyl acetate)-co-(vinyl alcohol)]-graft-poly(L-lactic 
acid) polymers were investigated. The preparation and characterization of the NC were 
previously described, emphasizing the gentle preparation technique of NC by spontaneous 
self-assembling of polymer and insulin (10). The subsequent trials with NC at healthy and 
diabetic rats demonstrated significant insulin uptake after nasal administration (11). The 
results motivated us to further investigate the enhancing effect of insulin absorption in a 
model biological environment for better understanding the performance of DEAPA-PVA-g-
PLLA nanocomplexes in vivo. As it is difficult to grow confluent layers of nasal epithelial 
cell layers (12), we utilize the well established human intestinal cell line Caco-2 as a model 
for epithelial cell layers. We compared the nanocomplexes against a nanoparticle preparation 
of P(26)-10LG polymer, which belongs in principle to the same polymer class of amine 
modified branched polyesters. In comparison to the watersoluble polymers P(26)-/,1,2,3LL
with short L-lactide side chains, the P(26)-10LG variant exhibited longer hydrophobic lactide-
co-glycolide chains. Particles therefrom were prepared with a solvent displacement technique
and afterwards loaded with insulin through adsorption on the positive particle surface. This 
concept was already successful utilized for the preparation of cationic particles for aerosol 
therapy (13), respectively adsorptive loading of tetanus toxoid on sulfobutylated (SB) SB-
PVA-g-PLGA particles and immunisation experiments on mice (14).
In the present study, the effect of DEAPA-PVA-g-PLLA NC and DEAPA-PVA-g-PLGA NP 
on the cellular response involving peptide absorption behavior was thus evaluated using the 
Caco-2 cell line. Viability and integrity of the cell monolayers, which affect the permeability 
of cell monolayers for peptide molecules and transport behaviour through the cell monolayer 
was examined. Furthermore we investigated the protection capabilities of the NC against the 
harsh attack of trypsinic enzymes, contributing essentially to luminal insulin degradation.   
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4.3. Materials and Methods
4.3.1. Materials
 Polymers: Poly[(vinyl-3-(diethylamino)-propylcarbamate-co-(vinyl acetate)-co-(vinyl alco-
hol)]-graft-poly(L-lactic acid), respective -poly(D,L-lactic-co-glycolic acid) polymers were 
synthesized and characterized as previously described (15). As abbreviation for the polymers 
we use: P(X)-YLL. P(26) carried 26 amino-groups per PVA molecule (DP=300). P(26)-1LL/
P(26)-2LL  had additional 32/ 48 short lactide chains (L-lactide) per backbone with an average 
chain length of about two/ three lactic acid units. P(26)-10LG  contains about 180 chains of 
lactide co- glycolide (PLGA) per PVA backbone with an average chain length of 12 units 
lactide/glycolide.
Human recombinant insulin (26.2 I.U./mg) was a gift from Aventis Pharma AG (Germany). 
Trypsin (TPCK treated, from bovine pancreas, 10.000 units/mg) and alpha-chymotrypsin 
(TLCK treated, Type VII, from bovine pancreas, 55 units/mg), lactate dehydrogenase assay 
and FITC-WGA were obtained from Sigma (Taufkirchen, Germany). Tissue culture reagents 
and fetal calf serum (FCS) were obtained from Gibco (Eggstein, Germany), and tissue culture 
articles from Nunc (Wiesbaden, Germany). All other chemicals were obtained from Merck 
(Darmstadt, Germany) in analytical quality. 
4.3.2. Nanocomplexes Preparation
The colloidal polymer-insulin complexes were prepared and characterized as previously 
described (10). Stock solutions of insulin (2.50 mg/mL) and polymers (2.50 – 12.50 mg/mL) 
were prepared in Tris (hydroxymethyl)-aminomethane (TRIS) buffer supplemented with 18 
mM glucose, 49 µM MgCl2, and 170 µM CaCl2 at a pH of 7.70 (0.01 M).  The 
nanocomplexes (NC) were obtained by spontaneous self-assembly after mixing of an 
equivalent volume of insulin and polymer stock solution.
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4.3.3. Nanoparticle Preparation
The particles of P(26)-10LL were prepared according to the solvent displacement technique 
(13). About 30,0 mg of polymer were dissolved in 4,0 ml acetone. The solution was slowly 
diluted via a syringe in 20,0 ml 0,01 % Pluronic F-68 solution containing 90,0 µg sodium 
carboxymethyl cellulose. The reaction mixture was stirred with a magnetic stirring bar at 400 
U⋅min-1 for 16 hours until total evaporation of the acetone. The  nanoparticle dispersion was 
mixed with an equal volume of insulin stock solution (2.50 mg/ml). The resulting insulin-
loaded nanoparticles were stable for 24 h, afterwards flocculation occurred. Insulin bounding 
efficiency, size and zeta potential were determined as previously described for the 
nanocomplexes (10).
4.3.4. Enzymatic degradation
Stock solutions of insulin with 1.0 mg/ml and the respective enzyme were prepared in Tris 
buffer pH 8.0 supplemented with 1.0 mM CaCl2. Both solutions were incubated for 15 min at 
37°C. Afterwards 5,0 ml insulin solution was mixed with ~ 50 µl enzyme solution resulting in 
a molar enzyme/insulin ratio of 1 : 173, according to the method of Schilling and Mitra (16).
Probes were incubated at 37°C and 100 µl samples withdrawn at preset time intervals and 
transferred to ice-cold Tris-buffer containing 1% trifluoracetic acid (TFA) to abort enzyme 
activity. The experiments were performed in triplicate. Samples were analyzed with HPLC.
4.3.5. Labeling of insulin with tetra-methyl-rhodamine isothiocyanate (TRITC)
 Insulin was dissolved at a concentration of 4.50 mg/mL in Na2CO3 buffer pH 9.30. A 
solution of TRITC (1.0 mg/mL) in dimethyl sulfoxide (DMSO) was quickly added (molar 
ratio of insulin/TRITC, 1:2.9) and the mixture stirred for 18 h at 4°C under light exclusion. 
The reaction was quenched with an excess of ammonium chloride and stirred for another 4 h. 
Separation was performed on a PD-10 column Sephadex G-25 (Amersham Bioscience, 
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Germany) with PBS pH 7.40. For the CLSM and uptake experiments the insulin stock-
solution for NC/NP preparation was mixed of labeled and non-labeled insulin solution 
according to a 1 : 10 (V/V) ratio. 
4.3.6. Cell culture
Mycoplasma-free Caco-2 cells were used at passage numbers 42-50 (HD, DKFZ, German 
Cancer Research Institute, Heidelberg, Germany) under conditions described earlier (17). 
Cells were seeded at a density of 6⋅104 cells/cm² either on cell culture dishes or on uncoated 
polycarbonate Transwell filter inserts (Costar, Bodenheim, Germany, 0.40 µm pore size, 
area: 4.71 cm²) and cultivated over 21 days. Medium was changed every second day.
4.3.7. Release of lactate dehydrogenase (LDH)
Caco-2 monolayers, grown on 12 well dishes (polystyrene) for 21 days, were incubated with 
one of the NC dispersions (1.0 mL), 0.1 % Triton X-100 in PBS (positive control) or pure 
PBS (negative control). After 60 and 120 min of exposure, 100 µL samples were taken and 
processed as described in (18). Each experiment was performed in triplicate. 
4.3.8.Transepithelial electrical resistance(TEER)
The integrity of the monolayer was checked at 21 day post seeding by measuring TEER 
before and after the experiment (19). The resistance of the monolayers in the present study
was approximately 400 ohms × cm-2. To study TEER reversibility, monolayers were rinsed 
with fresh transport buffer directly after the transport experiment and allowed to regenerate in 
fresh culture medium under conditions mentioned above. After preset time intervals of up to 
27 h monolayer integrities were checked in buffer and then buffer was replaced with fresh 
culture medium. Each experiment was run in triplicate. 
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4.3.9. Confocal laser scanning microscopy (CLSM)
Cells grown on filter inserts for 21 days were treated with NC-suspensions consisting of 
TRITC-labeled insulin and the polymers as described above. After 15, 60 and 120 min, cells 
were washed rigorously three times with ice-cold PBS, fixed with 3% (v/v) formalin in PBS 
at room temperature for 30 min and counterstained with FITC-labeled wheat germ agglutinin 
(WGA) (0.01µg/µL) for 30 min and DAPI (4’6-Diamidino-2-phenylindole) (1 µg/mL) for 20 
min, both under light exclusion. Filters were embedded in PBS/glycerol (2:1) and imaged by 
CLSM (Axiovert, Zeiss CLSM 501, Jena, Germany) equipped with a Zeiss Neofluor 
40*/1.3 objective. Excitation wavelengths were 364 nm (long pass filter (LP) 385 nm) for 
DAPI, 488 nm (LP 505 nm) for FITC and 543 nm (LP 560 nm) for TRITC. A gallery of 80 
optical sections (0.4 µm) was imaged and xz and yz composites were processed using Zeiss 
LSM 510 software. Sensitivity was kept constant during different experiments. 
4.3.10. Transport studies
Layer passage: Transport studies were performed 21 days post seeding. Filter inserts (Costar 
Transwells, 6 well) were rinsed with PBS supplemented with 15mM glucose pH 7.40 and 
allowed to equilibrate at 37°C for 15 min. Experiments were started by replacing the apical 
buffer with the test solution (1.5 mL)  and the basolateral buffer with fresh PBS (2.50 mL). 
Before replacing the buffer with NC dispersions, monolayers were washed once with Tris
buffer. After 2.5 h a sample (1.5 mL) was drawn from the basolateral chamber and analyzed 
by reversed-phase HPLC as previously described (10). Permeability in % was calculated from 
the concentration profiles using the following equation: (cumulative amount transported / 
initial amount)* 100. 
Layer uptake: After incubation of polystyrene 12 wells with transport buffer for 15 min at 
37°C and intermediate washing with supplemented Tris buffer, the test solutions (1.0 ml) 
were applied and incubated for 90 min. After removal of the NC solutions and a threefold 
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washing with PBS, the cells were dried up for 24 h under light exclusion. Each layer was 
afterwards dissolved in 300 µl 2.0 % Triton-X solution and the insulin-TRITC concentration 
measured with a Luminescence Spectrometer LS50B (Perkin Elmer). 
Results were expressed as mean value ± S.D. of three experiments. Significance between 
mean values was calculated using ANOVA one way analysis (GraphPad InStat version 3.00 
for Windows 95, GraphPad Software, San Diego, USA). Probability values p < 0.05 were 
considered significant. 
4.3.11. Surface Tension 
The Noüy Ring method (diameter 2,0 cm) was used to measure the surface tension. All 
measurements were performed in triplicate at 20°C. Maximum pull exerted on the ring by the 
surface is measured in mN⋅m-1 with a spring dynamometer against purificated water as 
control. The concentrations of the polymer solutions were 1.0 mg/ml.
4.4. Results and Discussion
4.4.1. Preparation of nanocomplexes and  nanoparticles 
Branched polyesters consisting of poly (vinyl alcohol) (PVA) grafted with chains of poly 
(lactic-co-glycolic acid) (PLGA), respectively poly (L-lactic acid) (PLLA) represent a new 
class of biodegradable polymers showing significant potential for the development of a 
variety of drug delivery vehicles (20). The modification of the PVA backbone by introduction 
of diethylamino-propylamine (DEAPA)-groups creates a polymer with positively charged 
functions and increases its hydrophilicity. The resulting amphiphilic DEAPA-PVA-g-PLLA 
polymer is characterized by a three-dimensional comb-like architecture with hydrophobic and 
hydrophilic moieties. By reduction of the PLLA units (≤ 3) for a PVA backbone with 8,5 % 
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amine substitution, corresponding to 26 DEAPA-groups, water-soluble polymers could be 
synthesized (15). We recently demonstrated the spontaneous formation of complexes by self-
assembly from these polymers with insulin (10). The resulting complexes were in the size 
range of 200-400 nm, exhibiting a positive zetapotential between +15-20 mV and an insulin 
association efficiency of about 75 % for a 1,25 mg/ml insulin solution. We compared the NC 
with a NP preparation based on the same backbone P(26), but with an increased grafting 
amount of PLGA, corresponding to about 180 chains per PVA with an average length of 12 
lactide-/glycolide-units. Dissolving of the hydrophobic P(26)-10LL polymer requires therefore 
an organic solvent and the blank particles were prepared by a solvent displacement technique. 
After complete removal of acetone by evaporation, nanoparticles were obtained in the narrow 
size range of 212 ± 29 nm, with a positive zetapotential of +41 ± 5 mV. The preformulated 
NP were loaded afterwards, by mixing with insulin solution. Peptide adsorption was 
confirmed by the inversion of the zetapotential to negative values of −18 ± 3 mV,
accompanied by a size increase to 424 ± 281 nm, indicating adsorption of negatively charged 
insulin on the positive particle surface. Insulin association efficiency, for a 1,25 mg/ml insulin 
solution, was found to be 89,8 ± 2,5 %. A comparable core-corona structure was described for 
the tetanus-toxoid adsorption on NP made of SB-PVA-g-PLGA (21). The driving force of 
adsorption, electrostatic and coulombic interactions, are the same as for the assembly of the 
NC. We compared the NP preparation against the NC in view of transport and cytotoxicity in 
the cell experiments.
4.4.2. Protection from enzymatic degradation of insulin in NC
In addition to promote its epithelial absorption, insulin must also be protected from digestive 
enzymes to provide the greatest amount of intact, biologically active insulin to be available 
for absorption. The utilized Caco-2 cells exhibit a high degree of differentiation resulting in a 
distinctive brush border enzyme pattern, like peptidases and hydrolases (22). Nevertheless, 
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the enzymatic degradation during epithelial transit is still moderate in comparison to the 
enzymatic environment during gastrointestinal passage. Especially the enzymes α-
chymotrypsin and trypsin, the major proteolytic enzymes secreted by the pancreas into the
intestinal lumen, account for the degradation of orally administered insulin (16). Therefore we 
utilized the both proteases to investigate the protection of insulin by NC from enzymatic 
degradation. 
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Figure 1. Enzymatic degradation of insulin (1,0 mg/ml) by alpha-chymotrypsin. The insulin 
control solution () exhibited a fast degradation, which was alleviated when insulin was 
incorporated in complexes with P(26)-1LL- (⋅-⋅⋅-⋅) respective P(26)-2LL – polymer (----).   
As presented in Figure 1, in the presence of α-chymotrypsin, free insulin was found to be 
markedly degraded. Indeed, under the experimental conditions only about 51.7 ± 0.4 % of the 
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initial concentration of insulin (1,0 mg/ml) remained undegraded within 60 min. By contrast, 
nanocomplexes of P(26)-1LL and -2LL decelerated the degradation for 30 min with an average 
10% higher insulin concentration recovered in this timeframe in comparison to the control. 
Beyond 30 min the effect continued only for the P(26)-2LL NC. The data for P(26)–NC are not 
shown as there was no significant difference in comparison to the control group.
In general, the insulin molecule consist of two chains, the A-chain with 21 amino acids and 
the B-chain with 30 amino acids, linked by two disulfide bonds. Protection from α-
chymotrypsin is difficult because of the numerous initial cleavage sides distributed all over 
the insulin molecule (B26-Tyr, A19-Tyr, B16-Tyr, B25-Phe and A14-Tyr). The shielding of 
the susceptible bonds would require an adequate embedding of the insulin molecule within 
the particle structure. As recently discussed (10), the complexes represent a state of 
equilibrium between polymer and insulin, characterized by exchange processes of binding 
partners. The uncomplexed insulin in solution is degraded very fast due to the high intrinsic 
acivity of α-chymotrypsin, Schilling found apparent Vmax of 6.48 x 10-6 (M/min) in 
comparison to trypsin with 0.75 x 10-6 (M/min) (16), whereby the equilibrium of the 
complexes is constantly shifted towards released insulin and dismantling of complexes. The 
longer lasting protection of P(26)-2LL NC is in accordance with its higher binding constant in 
comparison to P(26)-1LL NC (10). However, the insulin concentration profile in the presence 
of trypsin exhibited an excellent and long-lasting protection effect (Figure 2).
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Figure 2. Enzymatic degradation of insulin (1,0mg/ml) by trypsin. The nanocomplexes of 
insulin and P(26)- (⋅-⋅⋅-⋅), P(26)-1LL- (), respective P(26)-2LL – polymer (----) 
exhibited a significant protection against enzymatic attack in comparison to the unprotected 
insulin control solution (	). 
After one hour about 23.0 ± 2.8 % of the free insulin control solution with 1,0 mg/ml is 
degraded. In comparison, the NC decreased the degradation of insulin dependent on lactide-
grafting of the polymers. The complexes made of P(26) polymer reduced the degraded 
amount to 16,9 ± 1.5 %, P(26)-1LL NC to 12.0 ± 0.8 % and the best protection was realized 
with  P(26)-2LL NC, with a reduction to only 5.1 ±  0.8 % degraded insulin of the initial 1,0 
mg/ml. 
Trypsin itself cleaves insulin at only two sites, on the carboxyl side of residues B29-Lys and 
B22-Arg (23). Since the bonds susceptible to tryptic cleavage are located at the carboxyl 
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terminus of the B-chain, which is known as hydrophobic domain of insulin, it is obvious that 
the longer hydrophobic PLLA chains of P(26)-2LL could better interact and shield this 
segment.    
4.4.3 In vitro cytotoxicity studies
 A colloidal drug carrier designated for routine application should display as little cytotoxicity 
as possible and polycationic molecules have often been linked to cytotoxic reactions (24,25). 
Therefore we investigated the in vitro cytotoxicity of NC using various techniques. 
Membrane damaging effects were evaluated by the release of the cytosolic enzyme lactate 
dehydrogenase (LDH). The enzyme is found in almost all body tissues and released upon 
damaging of cells. 
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Figure 3. Left plot: LDH release after 60 and 120 min of buffer control and NC/NP 
composed of insulin and the respective polymers. NC´s of P(26)-2LL with a.) 2,125 mg/ml and 
b.) 6,25 mg/ml exhibited a concentration dependent increase of LDH release. Right plot:  In 
the investigated dilution series with 100, 50 and 25% of 6,25 mg/ml the dependence of LDH 
release is nearly linear to polymer concentration (---- linear fit with R = 0,9982).
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As shown in Figure 3 left, only a negligible release of LDH was observed after 60 and 120 
min for P(26), P(26)-1LL NC and P(26)-10LG NP, in comparison to the buffer control.
However, P(26)-2LL NC showed a significant increase of LDH-release, reaching 16.6 ± 7.2% 
after 60 min and 28.5 ± 4.1% after 120 min. This effect was concentration dependent and 
decreased linearly with decreasing concentration (Fig. 3 right).
Since all DEAPA-polymers have the same degree of amine-substitution with about 26 amine 
groups per PVA, the cytotoxic effects of P(26)-2LL NC must be due to other properties. A 
large number of amphiphilic, surfactant-like molecules used for absorption enhancing have 
been shown to have cytotoxic effects (26). We investigated the polymers in terms of surface 
activity with the Noüy Ring method (Figure 4). Each of the polymer solutions, with a
concentration of 1.0 mg/ml, exhibited a decrease of the surface tension from 55 mN/m for 
P(26) polymer to 46 mN/m for P(26)-2LL polymer in comparison to the pure Tris-buffer 
control with  69 mN/m. 
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Figure 4. Surface tension of polymer solutions. 
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The basic structure of the DEAPA-PVA-g-PLLA polymers is a polyvinyl alcohol, whose 
properties are mainly governed by the degree of polymerisation and the degree of hydrolyis. 
For the polymer synthesis we utilized a PVA with a hydrolysis degree of 86-89%. Aqueous 
solutions of such partially hydrolysed PVA grades decreases the surface tension of water and 
are therefore utilized as protective colloids (27). Even the very hydrophilic amine-modified 
P(26) backbone kept this basic characteristic. The hydrophobically modification by grafting 
with lactide side chains, leads to a more amphiphilic, surfactant-like character of the polymer. 
A similar increase in surface activity, dependent on the chain length of the introduced 
hydrophobic groups to partially hydrolysed PVA, was reported for PVA modifications with  
alkyl groups (28) or fatty acids (29). The negligible LDH release for NP of P(26)-10LG
correlates with its non-surfactant properties in aqueous solutions (30), as it is a hydrophobic 
organic-soluble polymer. Furthermore the positive charges at the particle corona are shielded 
by adsorbed insulin. 
The integrity of cell monolayers upon contact with the NC and NP was assessed by 
measuring the transepithelial electrical resistance (TEER). While P(26) – NC with 34 % and 
P(26)-10LG – NP with 38 % decrease of initial values, exhibited a moderate infuence on 
TEER in comparison to the buffer control with 10 % after 2,5 hours, resistance was 
significantly decreased with an increasing amount of lactide-grafting, being highest for P(26)-
2LL – NC (Figure 5). As observed for the release of lactate dehydrogenase this effect was 
concentration dependent. The P(26)-2LL - NC formulation with 2,125 mg/ml polymer 
concentration decreased the resistance to about 62 %, while a formulation with a threefold 
higher concentration decreased it to about 88 %. Again, this ranking is more likely related to 
the higher amphiphilic character of the grafted DEAPA-polymers with increasing number of 
lactic side chains, than to the cationic character caused by amine modification.
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Figure 5.  Reversibility of TEER decrease over 26 hours. Layer were incubated with 
nanocomplexes for 150 min followed by removal of NC, washing three times and further 
incubation with culture medium. Applied were a control solution (∆) and NC composed 
of insulin and /P(26) polymer (⋅-⋅Χ⋅-⋅), /P(26)-1LL polymer (---ο---), /P(26)-2LL polymer a.) 
with 2,125 mg/ml ( ⋅ θ  ⋅  ), b.) with 6,25 mg/ml (⋅⋅⋅∇⋅⋅⋅), /P(26)-10LG polymer ( ).
Both, the influence of positive charge and surface activity are reported to decrease epithelial 
resistance: For instance, a comparable reduction in transepithelial resistance was found for NP
made of chitosan (31), a biodegradable polymer with positive charges, respective for its 
solutions in a concentration dependent manner (32). For chitosan an influence of its positive 
charges on epithelial cells, resulting in structural reorganisations of tight junction associated 
proteins is discussed (33). Nevertheless the observed decrease in TEER upon contact with 
chitosan NP was reversible after removal (31). Furthermore, the effects of several absorption 
enhancing agents exhibiting surface activity on ephithelial integrity were studied on caco-2 
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cells (26,34). All of the wetting agents induced a concentration dependent decrease of 
resistance, whereas at intermediate concentrations, the effects were reversible. It was 
concluded that apical membrane wounds occurred, which were repaired when the enhancing 
agent were removed. 
In order to test the reversibility of NC and NP modulation on cellular permeability, the 
recovery of the initial monolayer electrical resistance was monitored over 27 h following 
washing with buffer and the incubation of cells with culture medium (Figure 5.). The curve 
progression of TEER observed for the control and P(26) - NC was not significantly different 
and resulted from the influence of TRIS-buffer used. The increase of TEER for the control 
after 20 and 27 h is probably connected to the differing conditions during measurement. 
While initial TEER measurements were performed after pre-incubation with transport buffer 
for 15 min, following measurements were performed directly after the replacement of medium 
with buffer. In general, all NC and NP made of grafted polymers exhibited a progressive 
reversibility of the epithelial resistance. The P(26)-2LL - NC, having shown the most dramatic 
decrease after 150 min, displayed a progressive and complete recovery after 17 h. TEER-
levels even increased to 234 ± 32% after 27 h. This final increase might be due to a 
reorganization of junctional-complexes after they have been damaged by the exposure to NC.
4.4.4. Confocal laser scanning microscopy
Confocal scanning microscopy was utilized to visualize a possible internalization of insulin 
NC into Caco-2 cell monolayers. Cells were incubated with NC prepared from different 
polymers and TRITC-labeled insulin over different time periods. To distinguish between the 
different cellular structures, cells were double-stained with FITC-WGA (membrane, green) 
and DAPI (nuclei, blue) (Figure 7a). The lectin WGA strongly binds to the tetra-saccharide 
N-acetylglucosamine, which is located abundantly at the apical membrane of Caco-2 cells. 
DAPI intercalates DNA and, therefore, was used as a marker for cell nuclei. As judged from 
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the xz and the yz sections in Figure 7, a significantly higher internalization of cell-associated 
insulin was found for all investigated NC compared to the control. When comparing
nanocomplexes of DEAPA-polymers, it was shown that the internalized TRITC fluorescence
varied strongly as a function of lactide-grafting. After 120 min, the following rank order was 
observed: P(26)-NC < P(26)-1LL-NC < P(26)-2LL-NC  (Figure 7b-d) after 120 min. This can 
be explained by the smaller size of the NC made of higher grafted versions, since it has been 
previously reported that smaller colloidal carriers achieve a higher internalization in 
adsorptive cells in comparison to larger ones (35). Another explanation might be cytotoxic
Figure 7. CLSM micrographs of Caco-2 monolayers treated over 120 min with 
nanocomplexes consisting of TRITC-labeled insulin (red fluorescence) and polymer: (a) 
insulin control, (b) P(26) - NC,  (c) P(26)-1LL, (d) P(26)-2LL. Cells were counterstained with 
DAPI (nuclei, blue) (white arrow) and FITC-WGA (membrane, green/yellowish) (yellow 
arrow). The blue arrows indicate dead cells. Data are presented as xy, xz and yz projections. 
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side effects described above. The damaging effects of P(26)-2LL-NC can even be seen from 
the micrographs. Cells, displaying a strong red color, are dead (Figure 7 d, blue arrow). 
In general, FITC-WGA staining was weaker after exposure to DEAPA-NC, indicating 
alterations in N-acetylglucosamine distribution in the apical membrane and, thereby, 
damaging effects. Comparable observations were reported for chitosan, with alterations of 
cytoskeletal organization, shortening of microvilli and weakening of actin staining after 
treatment of Caco-2 cells with different chitosan formulations (36). 
Following the time course of TRITC fluorescence internalization for e.g. P(26) – NC, the first 
fluorescence appeared 30 min just below apical membrane. It progressively moved to the 
basolateral sections, where it begins to appear after 60 min and intensified until 120 min.
These observations suggest a transcytotic mechanism of uptake for all NC. The slight 
perturbation of the plasma membrane, as indicated by the rise in extracellular LDH release, 
implicates an increased intracellular uptake suggesting an action of NC on the intracellular 
pathway as well. However, since fluorescence was distributed diffusely in the cytoplasm and 
was not found in discrete cytosolic vesicles, the lysosomal compartment seemed to be avoided 
and a different mechanism of uptake as described in (37) is presumable.
4.4.5. Transport studies
After having shown that insulin-NC were able to overcome the membrane and enter Caco-2 
cells, we wanted to quantify the internalization in and the transport through the monolayers 
using transport studies (Figure 8). Caco-2 monolayers were incubated with NC or pure insulin 
as a control. After 2.5 hours, the permeated amount of insulin in the acceptor part was
quantified by HPLC (Figure 8, upper plot). The layer uptake was determined after removal of 
the NC solutions and rigorous washing of the apical side followed by layer dissolution and 
TRITC fluorescence measurements of the cell lysis (Figure 8, lower plot).
101
0,0
0,5
1,0
0
5
10
15
20
25
i n
 
t h
e  
l a
y e
r
t h
r o
u
g h
 
t h
e  
l a
y e
r
%
 
o
f  i
n
i t i
a l
 
i n
s u
l i n
P ( 2
6 ) - 1
0 L L
-
N C
P ( 2
6 ) - 2
L L
-
N C
c :
 
6 , 2
5  m
g / m
l
P ( 2
6 ) - 2
L L
-
N C
c :
 
2 . 1
2 5
 
m
g / m
l
P ( 2
6 ) - 1
L L
-
N C
P ( 2
6 ) - N
C
I n s
u l i
n
C o
n t r
o l
Figure 8. Transport studies of TRITC labelled insulin. Upper plot: Percentage of initial 
concentration of insulin found in the costar transwell acceptor part. Lower plot: Percentage 
of initial concentration of insulin internalized in Caco-2 cell monolayers after 2,5 hours. 
Although transport remained below 1%, it was demonstrated that all NC-formulations were 
able to significantly enhance the transport through as well as the uptake in Caco-2 cells 
compared to pure insulin. Semiquantitative visual information obtained from CLSM images 
are in accordance with the results of the transport experiments. For internalization we 
observed again a ranking dependent on amount of lactic grafting for NC, being highest for 
P(26)-2LL-NC with about 25% of the applied insulin dose internalized after 2.5 hours. The 
performance of the P(26)-10LG - NP preparation with 10% uptake and 0,21 ± 0,1% transport, 
did not show considerable advantages in comparison to the complex formulations. 
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4.5. Conclusion
Colloidal carriers made of positively charged DEAPA polyesters revealed some interesting 
properties as drug delivery system for insulin. The comparison of permeability enhancing 
effects of nanocomplexes against a nanoparticle formulation, based on a high-grafted polymer 
version, showed no significant advantages for particles over complexes. However, 
nanocomplexes physico-chemical properties and interaction with Caco-2 monolayers varied 
strongly as a function of the polymer structural composition. The most effective variant 
posses a combination of a hydrophilic backbone and hydrophobic side chains. On the other 
hand, this combination led to a higher amphiphilic, surfactant-like character of the molecule, 
which probably caused damages to membrane and tight junctions, as indicated by LDH 
release and TEER decrease. However, since these effects seemed to be reversible and NC 
with a higher lactide-grafting showed the best protection capabilities, the highest 
internalization and transport through Caco-2 monolayers, it may be assumed that these NC are 
suitable carriers for insulin to overcome mucosal absorption barriers.
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Chapter 5
Summary and Outlook
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Summary
In this work biodegradable DEAPA-PVAL-g-PLLA nanocomplexes (NC) were investigated 
as a colloidal peptide carrier system for non-invasive transmucosal insulin delivery.
Chapter 1 describes the basic fundamentals of insulin therapy, current status, problems and 
future trends. The pathogenesis of diabetes mellitus and the different treatment options are 
discussed to give an understanding of the necessity for alternative non-invasive application 
systems. It was emphasized that epithelial barriers and enzymatic degradation prevent 
effective transmucosal insulin delivery.
The current status of the most promising industrial approaches for alternative delivery 
systems were highlighted. In addition, potential of colloidal biodegradable and bioadhesive
polymeric carriers for oral, pulmonal or nasal application of insulin were discussed. The 
factors bioadhesivity and complexing-capability of polymers were considered with regard to 
literature. Reference was made to other fields were charge modified grafted polyester of 
theses novel class were already succesfully utilized for drug delivery. The objectives of this 
work were defined.
In Chapter 2 the DEAPA-PVAL-g-PLLA polymers were characterized for their substitution 
degree of amine-groups and the extent of lactide grafting. It was possible to manipulate the 
hydrophilic-hydrophobic balance of these polyesters by factors such as molecular weight, 
PLLA chain lengths and degree of amine-substitution. Water solubility of these polymers 
allowed the spontaneous self-assembling with insulin to small nano-sized complexes with 
narrow size distribution without any mechanic emulsification procedures and without the use 
of surfactants. 
The formulation of nanocomplexes made of polymers with varying structural composition 
were characterized for various physico-chemical characteristics, such as size distribution, 
surface charge and insulin association efficiency. Studies with isothermal titration calorimetry 
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demonstrated the influence of the structural architecture on binding constants. An increase in 
binding affinity, drug loading, zeta potential and a decrease of complex size could be 
correlated with a higher substitution degree of DEAPA groups and a higher lactic acid 
grafting of the backbone.
Systemic investigations of the complexation process, using nephelometric and light scattering 
techniques, allowed the evaluation of an optimal ratio of the binding partners. The complexes
visualized by atomic force microscopy revealed a homogeneous particle collective with 
spheroidal complexes exhibiting an entangled internal structure.
In Chapter 3 the suitability of insulin containing DEAPA-PVAL-g-PLLA nanocomplexes as 
a nasal insulin delivery system was studied under in-vivo conditions at wistar rats. We 
investigated two different types of NC to evaluate polymer composition influences.
Changes in blood glucose and insulin concentration were monitored in anaesthetized rats 
using a glucose meter and ELISA. The blood glucose response revealed a significant decrease 
of glucose concentration, which was accompanied by an increase of exogenous insulin 
concentration in rat blood. From the investigated two different NC options, the more 
amphiphilic variant with grafted lactic acid side chains was superior to the more hydrophilic 
backbone with no additional grafting. The pharmacological response observed in healthy rats 
was reproduced on streptozotocin induced diabetic rats, demonstrating in-vivo effectivness in 
diseased subjects respectively. A significant increase in relative bioavailability was observed 
at higher polymer concentrations for the grafted variant. 
The histological examination of the nasal mucosa with light microscopy showed no signs of 
toxicity on nasal morphology at the site of application after a single administration procedure.
The results demonstrate that the NC significantly enhanced insulin absorption, suggesting that 
amphiphilic biodegradable comb-structured polymers could be a promising approach for nasal 
peptide delivery.
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In Chapter 4 the interaction of DEAPA-PVAL-g-PLLA nanocomplexes with enterocyte-like 
Caco-2 cells in terms of cytotoxicity, transport through and uptake in the cell layers was 
investigated. 
The NC were compared against a nanoparticle formulation based on a higher grafted variant 
of DEAPA-PVAL-g-PLGA and prepared by a solvent displacement technique. The 
preformulated NP were loaded with insulin by surface adsorption. The comparison of 
permeability enhancing effects of nanocomplexes with the nanoparticle formulation, showed 
no significant differences. However, nanocomplexes physico-chemical properties and 
interaction with Caco-2 monolayers varied strongly as a function of the polymer structural 
composition. The most effective carrier posses a combination of a hydrophilic backbone and 
hydrophobic side chains. On the other hand, this combination led to a higher amphiphilic, 
surfactant-like character of the polymer, which probably caused damages to membrane and 
tight junctions, as indicated by lactate dehydrogenase release and decrease of transepithelial 
resistance.
However, since these effects seemed to be reversible and NC with a higher lactide-grafting 
showed the best protection capabilities against trypsinic degradation, the highest 
internalization and transport through Caco-2 monolayers, it may be assumed that these NC are 
suitable carriers for insulin to overcome mucosal absorption barriers. 
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Outlook
Branched polyesters consisting of poly(vinyl alcohol) (PVA) modified with amine structures 
and grafted with short chains of poly (lactic acid) (PLA) represent a new class of 
biodegradable polymers showing significant potential for the development of a variety of drug 
delivery vehicles. The amphiphilic character and the water solubility of this class provide 
advantages when dealing with sensitive drug molecules such as peptides.
In this work, nanocomplexes (NC) based on these polyesters, as colloidal carrier for insulin 
and factors critical for complexation and delivery of insulin to the mucosal tissue of the nose 
were investigated. The imitation of the physiological postprandial insulin secretion with non-
invasive administration procedures is of great pharmaceutical interest. One of the main 
problems in this field is the finding of suitable insulin carrier systems. It is hoped, that the 
findings in this work may help to optimize and design a insulin delivery system for mucosal 
application required in the treatment of diabetes mellitus.
Moreover, further potential of the NC concept is based upon the potential transferability on 
other therapeutic important peptides. The modular design of the polymers allows for a 
structural engineering towards specific requirements, like complexation behavior or 
bioadhesion properties. These polymers are therefore a promising approach in the search for 
novel suitable excipients for peptide delivery systems in general. Further investigations are 
necessary to examine this potential.
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Titel
Insulin-Nanokomplexe gebildet durch Zusammenfügen mit aminmodifiziertem Poly(vinyl-
alkohol)-graft-poly(L-lactid) für die nicht invasive mukosale Applikation: Herstellung, 
Charakterisierung und in vivo Untersuchungen 
Zusammenfassung
In dieser Arbeit wurden bioabbaubare DEAPA-PVAL-g-PLLA Nano-Komplexe als 
kolloidales Protein-Trägersystem zur nicht-invasiven, transmukosalen Insulin-Applikation 
untersucht.  
Kapitel 1 beschreibt die Grundlagen der Insulin-Therapie, den Forschungsstand, sowie 
Probleme und zukünftige Entwicklungen. Die Entstehung von Diabetes Mellitus und die 
verschiedenen Behandlungsmöglichkeiten werden vorgestellt, um die bestehende Notwendig-
keit von alternativen, nicht-invasiven Applikationssystemen zu verdeutlichen. Es wurde 
herausgestellt das die Epithel-Barriere und der enzymatische Abbau eine effektive 
transmukosale Insulin-Aufnahme verhindern.
Der aktuelle Stand der vielversprechendsten industriellen Projekte für ein alternatives 
Darreichungssystem wird beschrieben. Darüberhinaus wird auf das Potential von kolloidalen 
bioabbaubaren und bioadhäsiven polymeren Trägern für orale, pulmonale und nasale 
Appplikation für Insulin hingewiesen. Faktoren wie Bioadhäsivität und Komplex-
Bildungsvermögen von Polymeren werden im Hinblick auf die Literatur erklärt. Es werden 
Beispiele aus anderen Bereichen angeführt, in denen Ladungs-modifizierte gepfropfte 
Polyester aus dieser neuartigen Klasse bereits erfolgreich eingesetzt wurden. Die 
Zielsetzungen dieser Arbeit werden definiert. 
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Im Kapitel 2 werden DEAPA-PVAL-g-PLLA Polymere bezüglich ihres Substitutionsgrades 
und des Pfropfungsgrades charakterisiert. Es war möglich durch Einstellung von Faktoren wie 
Molekulargewicht, PLLA Kettenlänge und Amin-Substitution, das hydrophile-hydrophobe 
Gleichgewicht der Polyester zu beeinflußen. Die Wasserlöslichkeit dieser Polymere 
ermöglichte deren spontanes Zusammenfügen mit Insulin zu kleinen Komplexen im 
Nanometer-Bereich mit enger Größenverteilung, ohne Anwendung von mechanische 
Emulgierschritten und ohne Zusatz von Emulgatoren.
Die Herstellung der Nano-Komplexe aus Polymeren mit unterschiedlicher struktureller 
Zusammensetzung wurde im Hinblick auf Größenverteilung, Oberflächenladung und Insulin-
Bindungskapazität beschrieben. Untersuchungen mit isothermaler Titrationskalorimetrie 
zeigten den Einfluß von Strukturmerkmalen auf die Bindungskonstante. Ein Anstieg der 
Bindungsaffinität, der Beladung, des Zetapotentials und eine Verringerung der Komplexgröße 
konnte mit einem höheren Substitutionsgrad von DEAPA-Gruppen und einem höheren 
Pfropfungsgrad des Rückgrates korreliert werden. Eine systematische Untersuchung des 
Komplexbildungsprozesses mit Hilfe von Trübungsmessungen und Streulichtmethoden, 
ermöglichte die Ermittlung von optimalen Verhältnissen der Bindungspartner. Die Komplexe 
wurden mit Hilfe von Rasterkraftmikroskopie dargestellt und zeigten ein homogenes 
Partikelkollektiv mit sphärischen Komplexen und einer knäuelartigen internen Struktur.
Im Kapitel 3 wurde die Eignung von Insulin DEAPA-PVAL-g-PLLA Nano-Komplexen für 
die nasale Insulin-Applikation in-vivo an Wistar-Ratten untersucht. Es wurden zwei 
verschiedene Komplexvarianten untersucht, um den Einfluß der Polymerstruktur zu 
beurteilen. Änderungen der Glukose - und Insulinkonzentration im Blut der betäubten Ratten 
wurde mit Hilfe eines Blutzuckermessgerätes und ELISA verfolgt. Der Verlauf der 
Blutglukose zeigte einen signifikanten Abfall der Glukosekonzentration, begleitet von einer 
ansteigenden Konzentration exogenen Insulins im Rattenblut. Von den beiden untersuchten 
Komplextypen zeigte sich die amphiphile gepfropfte Variante, im Vergleich zu dem 
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hydrophilen Rückgrat ohne Pfropfung, als besser geeignet.  Der pharmakologische Effekt, der 
an gesunden Ratten beobachtet wurde, konnte an  Streptozotocin induzierten, diabetischen 
Ratten wiederholt werden und zeigte die in-Vivo Wirkung damit auch an der eigentlichen 
erkrankten Zielgruppe. Ein signifikanter Anstieg der relativen Bioverfügbarkeit wurde bei 
höheren Konzentrationen der gepfropften Variante beobachtet.
Nach einmaliger Applikation der Nano-Komplexe zeigten die histologischen Untersuchungen 
der nasalen Mukosa mit dem Lichtmikroskop keine toxischen Effekte auf das nasale 
Zellgewebe am Applikationsort. Die signifikante Insulin-Aufnahme mit Hilfe von Nano-
Komplexen zeigt, das amphiphile bioabbaubare und kammartig-verzweigte Polymere, einen 
vielversprechenden Ansatz für ein nasales Protein-Trägersystem darstellen.   
Im Kapitel 4 wird die Wechselwirkung von DEAPA-PVAL-g-PLLA Nano-Komplexen mit 
der Darmzelllinie Caco-2 im Hinblick auf Zelltoxizität, Transport durch und Aufnahme in die 
Zellschicht untersucht. 
Die Nano-Komplexe wurden mit einer Nano-Partikel Formulierung verglichen, die aus einer 
stark gepfropften Variante von DEAPA-PVAL-g-PLGA mittels Solvent-Displacement-
Verfahren hergestellt wurde. Die vorgefertigten Nano-Partikel wurden durch Adsorption von 
Insulin an die Partikeloberfläche beladen. Der Vergleich der Insulin-Aufnahme fördernden 
Wirkung zeigte keinen signifikanten Unterschied zwischen Partikel- und Komplex-
Formulierung. Allerdings zeigten die physiko-chemischen Eigenschaften der Nano-Komplexe 
und deren Wechselwirkung mit Caco-2 Zellen eine starke Abhängigkeit von der 
Polymerstruktur. Die erfolgreichste Variante bestand aus einem hydrophilen Rückgrat und 
hydrophoben Seitenketten. Diese Kombination verstärkt jedoch den amphiphilen Charakter 
des Polymers und damit seine Oberflächenaktivität. Eine Eigenschaft die möglicherweise 
Schäden an der Membran und den Tight Junctions verursachte, wie durch LDH Freisetzung 
und den Abfall des transepithelialen Widerstandes angedeutet wurde.   
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Nicht zuletzt weil dieser Effekt reversibel war und Nano-Komplexe mit höherem 
Propfungsgrad den besten Schutz vor Trypsin-Abbau, die höchste Zellaufnahme und den 
höchsten Transport durch Caco-2 Zellen aufwiesen, scheint dieses Trägersystem für Insulin 
geeignet zu sein mukosale Aborptionsbarrieren zu überwinden.
Ausblick
Verzweigte Polyester, bestehend aus Amin-modifiziertem Polyvinylalkohol mit gepfropften 
kurzen PLA-Ketten, stellen eine neue Klasse von bioabbaubaren Polymeren mit großem
Potential für die Entwicklung von Arzneistoff-Trägersystemen dar. Der amphiphile Charakter 
und die Wasserlöslichkeit dieser Klasse bieten Vorteile im Umgang mit sehr empfindlichen, 
peptidischen Arzneistoffen.  
In dieser Arbeit wurden Nano-Komplexe, basierend auf diesen Polyestern, als kolloidaler 
Träger für Insulin und die Faktoren, die für eine effektive Komplexierung und Zuführung zu 
den Schleimhäuten der Nase als kritisch angesehen werden, wurden untersucht. Die 
Nachahmung der physiologischen postprandialen Insulin-Ausschüttung mit Hilfe einer nicht-
invasiven Applikationtechnik ist von großem pharmazeutischen Interesse. Eines der größten 
Probleme in diesem Zusammenhang ist die Auffindung geeigneter Trägersysteme. Es ist zu 
hoffen, daß die Ergebnisse dieser Arbeit bei der Entwicklung und Optimierung zukünftiger 
Insulin-Trägersysteme zur mukosalen Applikation hilfreich sind, welche einmal der Diabetes 
Behandlung dienen könnten.
Darüberhinaus besitzt das NC-Konzept weiteres Potential im Hinblick auf die mögliche 
Übertragbarkeit auf andere therapeutisch wichtige peptidische Arzneistoffe. Der modulare 
Aufbau der Polymere erlaubt die strukturelle Anpassung an spezielle Anforderungen, wie 
Komplexierungsverhalten oder bioadhäsive Eigenschaften. Die Polymere sind daher ein 
vielversprechender Ansatz für ein allgemeines Protein-Trägersystem. Weitere Forschung ist 
notwendig um diese Möglichkeiten zu untersuchen.
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Abbreviations
AFM atomic force microscopy Mw molecular weight
AMI aqueous mist inhaler MALLS multi angle laser light scattering
ANOVA analysis of variance NC nanocomplexes
AUC area under the curve NIDDM non-insulin-dependent diabetes 
mellitus
CDI carbonyl di-imidazole NMP N-methyl pyrrolidone
CLSM confocal laser scanning microscopy NMR nuclear magnetic resonance
DAPI diamidino-phenylindole NP nanoparticles
DEAPA diethyl-amino-propylamine NPH neutral protamine Hagedorn
DMSO dimethyl sulfoxide PEC polyelectrolyte complexes
DNA desoxyribonucleic acid pI point of isocharge
DPI dry powder inhalers PLGA poly(D,L-lactic-co-glycolic acid)
DS degree of substitution PLLA poly(L-lactic acid)
ELISA enzyme-linked-immuno-sorbent 
assay
pMDI pressurized meterd dose inhaler
FCS fetal calf serum PBS phosphate buffered saline
FDA food and drug administration PEO polyethylene oxide
FITC fluorescein isothiocyanate PVA poly(vinyl alcohol)
GALT gut associated lymphoid tissue SB sulfobutylated
GIT gastrointestinal tract s.c. subcutaneously
GPC gel permeation chromatography SDS sodium dodecyl sulfate
HD Caco-2 cell line from Heidelberg TEER transepithelial electrical resistance
H.E. hematoxylin and eosin TFA trifluoracetic acid
HIM hexyl-insulin-monoconjugate THF tetrahydrofuran
HPLC high performance liquid 
cromatography
TLCK tosyl-L-lysine chloromethyl 
ketone
IDDM insulin-dependent diabetes mellitus TPCK tosylamide-phenylethyl-
chloromethyl ketone
ITC isothermal titration calorimetry TRIS tris(hydroxymethyl)aminomethane
I.U. international units TRITC tetra-methyl-rhodamine 
isothiocyanat
LDH lactate dehydrogenase WGA wheat germ agglutinin
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